US20100158881A1 - Activated dual specificity lymphocytes and their methods of use - Google Patents
Activated dual specificity lymphocytes and their methods of use Download PDFInfo
- Publication number
- US20100158881A1 US20100158881A1 US12/715,829 US71582910A US2010158881A1 US 20100158881 A1 US20100158881 A1 US 20100158881A1 US 71582910 A US71582910 A US 71582910A US 2010158881 A1 US2010158881 A1 US 2010158881A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- lymphocytes
- lymphocyte
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title abstract description 33
- 230000009977 dual effect Effects 0.000 title description 45
- 239000000427 antigen Substances 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 95
- 102000036639 antigens Human genes 0.000 claims abstract description 95
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims abstract description 48
- 108091008874 T cell receptors Proteins 0.000 claims abstract description 47
- 108700010039 chimeric receptor Proteins 0.000 claims abstract description 43
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 14
- 238000001727 in vivo Methods 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 151
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 134
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 62
- 230000000735 allogeneic effect Effects 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 108020003175 receptors Proteins 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 26
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 24
- 201000001441 melanoma Diseases 0.000 claims description 16
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 claims description 13
- 210000004443 dendritic cell Anatomy 0.000 claims description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 9
- 210000004988 splenocyte Anatomy 0.000 claims description 7
- 210000004976 peripheral blood cell Anatomy 0.000 claims description 5
- 230000002463 transducing effect Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000003053 immunization Effects 0.000 abstract description 24
- 238000002649 immunization Methods 0.000 abstract description 22
- 230000001225 therapeutic effect Effects 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 description 62
- 108010002350 Interleukin-2 Proteins 0.000 description 62
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 59
- 238000011282 treatment Methods 0.000 description 31
- 150000007523 nucleic acids Chemical group 0.000 description 21
- 230000001177 retroviral effect Effects 0.000 description 21
- 239000013598 vector Substances 0.000 description 19
- 230000009257 reactivity Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 16
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 206010033128 Ovarian cancer Diseases 0.000 description 15
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 14
- 238000001802 infusion Methods 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 238000010361 transduction Methods 0.000 description 14
- 230000026683 transduction Effects 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 238000012546 transfer Methods 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 102000009109 Fc receptors Human genes 0.000 description 10
- 108010087819 Fc receptors Proteins 0.000 description 10
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 210000002865 immune cell Anatomy 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 102000009438 IgE Receptors Human genes 0.000 description 5
- 108010073816 IgE Receptors Proteins 0.000 description 5
- 108010073807 IgG Receptors Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000003306 harvesting Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- 229930193140 Neomycin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000001415 gene therapy Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 4
- 229960004927 neomycin Drugs 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 3
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 3
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 3
- 241000713869 Moloney murine leukemia virus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000013211 curve analysis Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 206010028116 Mucosal inflammation Diseases 0.000 description 2
- 201000010927 Mucositis Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 108700042075 T-Cell Receptor Genes Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 210000005220 cytoplasmic tail Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000001638 lipofection Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- -1 0.1-2.0M) Chemical compound 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010069802 Device related sepsis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 101710168592 Gag-Pol polyprotein Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010035452 HLA-A1 Antigen Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024218 Lentigo maligna Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- 206010025652 Malignant melanoma in situ Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 239000004107 Penicillin G sodium Substances 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008211 brain sarcoma Diseases 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000020888 liquid diet Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 235000019369 penicillin G sodium Nutrition 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the field of the present invention relates generally to compositions and methods for the treatment or prevention of diseases in mammals. More specifically, this invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and/or chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens and to preventative, diagnostic and therapeutic applications which employ these lymphocytes.
- TCR T cell receptor for antigen
- MHC major histocompatibility complex
- CD3 CD3 is assumed to be responsible for intracellular signaling following occupancy of the TCR by ligand.
- TCR/CD3 The T cell receptor for antigen-CD3 complex (TCR/CD3) recognizes antigenic peptides that are presented to it by the proteins of the major histocompatibility complex (MHC). Complexes of MHC and peptide are expressed on the surface of antigen presenting cells and other T cell targets. Stimulation of the TCR/CD3 complex results in activation of the T cell and a consequent antigen-specific immune response.
- the TCR/CD3 complex plays a central role in the effector function and regulation of the immune system.
- T cell receptor for antigen Two forms of T cell receptor for antigen are expressed on the surface of T cells. These contain either ⁇ / ⁇ heterodimers or ⁇ / ⁇ heterodimers. T cells are capable of rearranging the genes that encode the ⁇ , ⁇ , ⁇ and ⁇ chains of the T cell receptor. T cell receptor gene rearrangements are analogous to those that produce functional immunoglobulins in B cells and the presence of multiple variable and joining regions in the genome allows the generation of T cell receptors with a diverse range of binding specificities. Each ⁇ / ⁇ or ⁇ / ⁇ heterodimer is expressed on the surface of the T cell in association with four invariant peptides. These are the ⁇ , ⁇ and ⁇ subunits of the CD3 complex and the zeta chain.
- the CD3 ⁇ , ⁇ and ⁇ polypeptides are encoded by three members of the immunoglobulin supergene family and are found in a cluster on human chromosome 11 or murine chromosome 9.
- the zeta chain gene is found separately from other TCR and CD3 genes on chromosome 1 in both the mouse and human.
- Murine T cells are able to generate a receptor-associated ⁇ chain through alternative splicing of the zeta mRNA transcript.
- the CD3 chains and the zeta subunit do not show variability, and are not involved directly in antigen recognition.
- T cell receptor All the components of the T cell receptor are membrane proteins and consist of a leader sequence, externally-disposed N-terminal extracellular domains, a single membrane-spanning domain, and cytoplasmic tails.
- the ⁇ , ⁇ , ⁇ and ⁇ antigen-binding polypeptides are glycoproteins.
- the zeta chain has a relatively short ectodomain of only nine amino acids and a long cytoplasmic tail of approximately 110 amino acids.
- Most T cell receptor ⁇ / ⁇ heterodimers are covalently linked through disulphide bonds, but many ⁇ receptors associate with one another non-covalently.
- the zeta chain quantitatively forms either disulphide-linked ⁇ - ⁇ heterodimers or zeta-zeta homodimers.
- Fc receptor Another example of a type of receptor on cells of the immune system is the Fc receptor.
- effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation, phagocytosis and target cell lysis. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells.
- FcRs structural heterogeneity of Fc receptors
- FcRs are defined by their specificity for immunoglobulin isotypes.
- Fc receptors for IgG are referred to as Fc ⁇ R, for IgE as Fc ⁇ R, for IgA as Fc ⁇ R, etc.
- Structurally distinct receptors are distinguished by a Roman numeral, based on historical precedent.
- Three groups of Fc ⁇ Rs, designated Fc ⁇ RI, Fc ⁇ RII, and Fc ⁇ RIII are now recognized. Two groups of Fc ⁇ R have been defined; these are referred to as Fc ⁇ RI and Fc ⁇ RII.
- Structurally related although distinct genes within a group are denoted by A, B, C.
- the protein subunit is given a Greek letter, such as Fc ⁇ RIIIA ⁇ , Fc ⁇ RIIIA ⁇ .
- the low affinity receptor for IgG is composed of the ligand binding CD16 ⁇ (Fc ⁇ RIIIA ⁇ ) polypeptide associated with the ⁇ chain (Fc ⁇ RIIIA ⁇ ).
- the CD16 polypeptide appears as membrane anchored form in polymorphonuclear cells and as transmembrane form (CD16TM) in NK.
- the Fc ⁇ RIIIA serves as a triggering molecule for NK cells.
- IL-2 receptor Another type of immune cell receptor is the IL-2 receptor. This receptor is composed of three chains, the ⁇ chain (p55), the ⁇ chain (p75) and the ⁇ chain. When stimulated by IL-2, lymphocytes undergo proliferation and activation.
- Antigen-specific effector lymphocytes such as tumor specific T cells (Tc) are very rare, individual-specific, limited in their recognition spectrum and difficult to obtain against most malignancies. Antibodies, on the other hand, are readily obtainable, more easily derived, have wider spectrum and are not individual-specific.
- the major problem of applying specific antibodies for cancer immunotherapy lies in the inability of sufficient amounts of monoclonal antibodies (mAb) to reach large areas within solid tumors. In practice, many clinical attempts to recruit the humoral or cellular arms of the immune system for passive anti-tumor immunotherapy have not fulfilled expectations. While it has been possible to obtain anti-tumor antibodies, their therapeutic use has been limited so far to blood-borne tumors [Lowder, J. N. et al. Cancer Surv.
- TILs tumor-infiltrating lymphocytes
- a strategy which has been developed allows one to combine the advantage of the antibody's specificity with the homing, tissue penetration, cytokine production and target-cell destruction of T lymphocytes and to extend, by ex vivo genetic manipulations, the spectrum of anti-tumor specificity of T cells.
- Chimeric T cell receptor (cTCR) genes composed of the variable region domain (Fv) of an antibody molecule and the constant region domain of the antigen-binding TCR chains, i.e., the ⁇ / ⁇ or ⁇ / ⁇ chains have been expressed in T cells and found to be functionally active.
- Adoptive immunotherapies using tumor infiltrating lymphocytes and IL-2 have been developed for some cancers. These therapies have resulted in significant long-term responses in some patients with melanoma.
- one object of the present invention is to produce an activated chimeric receptor-transduced lymphocyte capable of binding to and obliterating cancer cells.
- One particular object of the present invention is to increase the effectiveness of adoptive immunotherapy by increasing the persistence and/or activity of adoptively transferred T cells by activating a pre-selected population of adoptively transferred lymphocytes with in vivo immunization.
- Another objective of the invention is to create dual specific T cells by genetic modification so that each individual T cell is reactive with both a strong antigen, such as, for example an alloantigen or other foreign agent, and the tumor.
- the strong antigen is used both to expand and activate the cells in vitro and in vivo.
- the present invention relates to a composition
- a composition comprising a population of T cells transduced with a chimeric receptor gene and pre-selected for reactivity with a strong antigen.
- Another embodiment of the present invention comprises a lymphocyte having a TCR directed to a specific strong antigen and a chimeric T-cell receptor directed to a tumor antigen, wherein the lymphocyte has been activated in vivo by the strong antigen.
- Such cells exhibit strong anti-tumor response and provide a recipient of such cells with a protection from tumor challenge, i.e. prophylactic response, and an anti-tumor treatment.
- the method of treating a patient with therapeutically-activated dual-specificity lymphocytes comprises the steps of expanding a patient's lymphocytes with one or more specific strong antigens ex vivo, transducing the lymphocytes with a chimeric receptor gene, introducing the transduced lymphocytes into the patient and immunizing the patient with the strong antigents) in vivo.
- a preferred embodiment of the present method utilizes an alloantigen as the strong antigen.
- Another preferred embodiment utilizes a virus or other foreign antigen as the strong antigen.
- the present invention also relates to a method of treating a patient with dual specificity lymphocytes having reactivity to one or more pre-selected strong antigens comprising the steps of administering an effective amount of such lymphocytes to a patient and immunizing the patient with the strong antigen.
- the present invention relates to activated dual specific lymphocytes containing chimeric genes suitable to endow lymphocyte cells with antibody-type specificity and T-cell receptors specific for one or more pre-selected strong antigens.
- Various types of lymphocytes are suitable, for example, natural killer cells, helper T cells, suppressor T cells, cytotoxic T cells, lymphokine activated cells, subtypes thereof and any other cell type which can express chimeric receptor chain.
- the present invention further relates to pharmaceutical, prophylactic and curative compositions containing an effective quantity of such cells.
- FIG. 1 shows a model of the dual-specific T cell created by genetic modification such that each individual T cell has specificity for both the strong antigen/immunogen and tumor.
- the chimeric receptor enables tumor recognition and comprises single-chain antibody variable regions (scFv) connected to TCR signaling chains, such as the ⁇ chain of the Fc receptor.
- scFv single-chain antibody variable regions
- FIG. 2 shows the results of treating 8 advanced ovarian cancer patients with MOv-PBL infusion. Specifically, treatment was measured by the percentage of circulating MOv- ⁇ transduced lymphocyte cells following MOv-PBL infusion.
- FIGS. 3A and 3B show the in vivo effects of allogeneic immunization of adoptively transferred T cells in mice spleen, lung, and blood upon immunization with allo-splenocytes (A) and alto-DC (dendritic cells; B) as a measure of Thy 1.1 cells in tissue.
- FIG. 4 shows the phenotypic results of dual specific mouse T cells, where these T cells express the chimeric MOv-y.
- FIG. 5 shows that mice are protected against tumor challenge when infused with dual specific T cells followed by immunization with allogeneic splenocytes.
- FIG. 6 shows a time course graph of the adoptive transfer of dual specific T cells followed by immunization treatment of established subcutaneous tumor in immunodeficient mice. The results show that dual specific T cells inhibit tumor growth and that the effect is augmented by immunization.
- FIG. 7 demonstrates that dual specific MOv- ⁇ transduced human T cells capable of recognizing both allogeneic cells and ovarian cancer cells can be generated in vitro by using PBMC from patients (363 and 399), transducing with MOv-y, and stimulating with PBMC from donor (269).
- the graph shows that transduced and non transduced cells released GM-CSF in response to donor 269 PBMC.
- transduced patient (363 and 399) cells released significant amounts of GM-CSF in response to IGROV, indicating that these transduced T cells were allogeneic- and IGROV-reactive.
- FIGS. 8A-8F shows the phenotypic results of the bulk population of T cells from patient 399 anti-269 (A-C) and of patient 363 anti-269 (D-F), where 8 C and 8 F demonstrate that the T cells express the chimeric MOv- ⁇ receptor.
- FIG. 9 shows the functional assay results from bulk MOv- ⁇ transduced T cells of patient 410, where T cells are both allo- and IGROV-reactive as measured by GM-CSF release (pg/ml).
- FIGS. 10A-B show the phenotypic results of bulk MOv-y transduced T cells of patient 410 (anti-556 donor), where the T cells are primarily CD4+ and do in fact express the chimeric MOv- ⁇ receptor.
- FIGS. 11A-11J show the phenotypic results of individual daughter clones from the bulk MOv- ⁇ transduced T cells of patient 410 (anti-556 donor).
- FIGS. 11A-11E show that the T cells express the chimeric MOv- ⁇ receptor, as demonstrated by the shift in peak on the X-axis.
- FIGS. 11F-11J demonstrate by FACS whether the clone is CD4 or CD8.
- FIGS. 12A-12D show growth curve analysis of responder cells transduced with dual specific T cells following stimulation with various allogeneic cell types (PBMC, DC, or B cells) and control at varying stimulator:responder ratios.
- PBMC allogeneic cell types
- FIGS. 13A-13D show growth curve analysis of responder cells transduced with dual specific T cells following restimulation with various allogeneic cell types (PBMC, DC, or B cells) and control at varying stimulator:responder ratios.
- PBMC allogeneic cell types
- FIG. 14 shows growth curve analysis of alloreactive T cells in MLR with various concentrations of IL-2.
- FIG. 15 shows the MFG-MOv- ⁇ -I-N retroviral vector.
- Nucleic acid sequences include, but are not limited to, DNA, RNA or cDNA.
- Substantially homologous as used herein refers to substantial correspondence between the nucleic acid sequence for the V-J or V-D-J junctional sequences for the ⁇ and ⁇ chains of the tumor antigen specific T-cell receptors provided herein and that of any other nucleic acid sequence.
- substantially homologous means about 50-100% homology, preferably by about 70-100% homology, and most preferably about 90-100% homology between the nucleic acid sequences and that of any other nucleic acid sequence.
- substantially homologous as used herein also refers to substantial correspondence between the amino acid sequence of the V-J or V-D-J junctional sequences of the antigen specific T-cell receptors provided herein and that of any other amino acid sequence.
- MHC Major Histocompatibility Complex
- HLA human leukocyte antigens
- cancer includes but is not limited to, melanoma, epithelial cell derived cancers, lung cancer, colon cancer, ovarian cancer, breast cancer, kidney cancer, prostate cancer, brain cancer, or sarcomas.
- melanoma includes, but is not limited to, melanomas, metastatic melanomas, melanomas derived from either melanocytes or melanocyte related nevus cells, melanocarcinomas, melanoepitheliomas, melanosarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, invasive melanoma or familial atypical mole and melanoma (FAM-M) syndrome.
- the aforementioned cancers can be treated, assessed or diagnosed by methods described in the present application.
- the lymphocytes of the present invention are pre-selected for TCRs having reactivity with specific antigens. These antigens are preferably strong antigens.
- strong antigen as it is referred to herein relates to an antigen capable of inducing proliferation of pre-selected adoptively transferred T cells. Examples of such antigens include but are not limited to alloantigens, viral agents and other foreign agents. Allogeneic agents or “alloantigens” are antigens derived from genetically non-identical members of the same species. Allogeneic tissues, cells, proteins, peptides, nucleic acids and/or other cellular components may be used to select an individual or subpopulation of lymphocytes.
- viral agents include, but are not limited to, Epstein Barr virus and the Flu-virus and proteins, peptides, nucleic acids and other cellular components derived therefrom.
- strong antigens include foreign proteins such as serum proteins from other species including bovine.
- “Dual specificity lymphocytes” as that phrase is used herein refers to lymphocytes capable of reacting with both a tumor antigen and a pre-selected strong antigen.
- the tumor antigen reactivity may be conferred by genetically modifying lymphocytes with a chimeric T cell receptor gene encoding a binding site for the tumor antigen. Tumor antigen reactivity may also be conferred by native TCR itself. Reactivity with the pre-selected strong antigen(s) is preferably conferred by in vitro expansion of the isolated population of lymphocytes by specific T cell activation using one or more pre-selected strong antigens.
- Chimeric receptor gene refers to any receptor gene encoding a protein containing an extracellular recognition/binding site and transmembrane and intracellular portions capable of translating the binding of a ligand to the recognition site to specific intracellular activities.
- the chimeric receptor gene encodes sequences for T-cell receptors or parts thereof which recognize tumor associated antigens and/or function to translate extracellular/cytoplasmic signal to intracellular activities in T-cells.
- One example of such a chimeric receptor gene encodes a single chain variable region from a monoclonal antibody joined to the Fc receptor chain capable of mediating T-cell receptor signal transduction.
- Another preferred chimeric receptor comprises an antibody variable region joined to the cytoplasmic region of CD28 from a T cell or a similar region which can provide a T cell with co-stimulation signals.
- immune cell trigger molecules are any one of the IL-2 receptor (IL-2R) p55 ( ⁇ ) or p75 ( ⁇ ) or ⁇ chains, especially the p75 and ⁇ subunits which are responsible for signaling T cell and NK proliferation.
- IL-2R IL-2 receptor
- Further candidate receptor molecules for creation of scFv chimeras in accordance with the present invention include the subunit chains of Fc receptors.
- the most attractive candidates are the ⁇ - and CD16 ⁇ -subunits of the low affinity receptor for IgG, Fc ⁇ RIII. Occupancy or cross-linking of Fc ⁇ RIII (either by anti-CD16 or through immune complexes) activates NK cells for cytokine production, expression of surface molecules and cytolytic activity [Unkeless, J. C. et al., Annu. Rev. Immunol. 6:251-281 (1988); Ravetch, J. V. and Kinet, J. P. Annu. Rev. Immunol.
- the Fc ⁇ RIII appears as a heterooligomeric complex consisting of a ligand-binding a chain associated with a disulfide-linked ⁇ or zeta chain.
- the Fc ⁇ RIIIA signalling gamma chain [Wirthmuller, V. et al., J. Exp. Med. 175:1381-1390 (1992)] serves also as part of the Fc ⁇ RI complex, where it appears as a homodimer, is very similar to the CD3 zeta chain, and in fact can form heterodimers with it in some cytolytic T lymphocytes (CTL) and NK cells [Orloff, D.
- the chimeric receptor genes encode amino acid sequences which provide for the V-J or V-D-J junctional regions or parts thereof for the alpha and beta chains of the T-cell receptor which recognize tumor associated antigens.
- the chimeric T-cell receptors recognize or bind tumor associated antigens presented in the context of MHC Class I.
- tumor antigen can be defined as a molecule that can be used to target therapy against a tumor and includes those antigens only found on tumor cells (i.e. tumor specific), those which are expressed on tumor cells and on limited normal tissues, i.e.
- differentiation antigens including cancer-testis antigens and those which are over-expressed on tumor cells compared to the expression on a wide variety of normal tissues (i.e. over-expressed antigens).
- over-expressed antigens include, but are not limited to, Folate binding protein (FBP), Erb-B2, GD-2, HMW-MAA, G250, TAG-72, NY-ESO-1, carcino-embryonic antigen and alpha-fetoprotein.
- FBP Folate binding protein
- Erb-B2 Erb-B2
- HMW-MAA G250
- TAG-72 TAG-72
- NY-ESO-1 NY-ESO-1
- carcino-embryonic antigen and alpha-fetoprotein.
- Differentiation antigens include, for example, Tyrosinase, MART-1, MAGE and gp100 of melanoma.
- Tumor-specific antigens include, for example, mutant Ras, mutant p53, mutant Erb-B2 of a wide variety of tumors including breast and colon. Any of these tumor antigens can serve as the binding agent for the TCR or chimeric receptor. The choice of which antigen to target is within the skill of the ordinary artisan, and is based upon the specific tumor being targeted.
- the tumor associated antigens recognized by the receptors of this invention are melanoma antigens.
- melanoma specific T-cell receptors may recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1.
- melanoma antigens which are recognized by the chimeric receptors include, but are not limited to, MART-1, or peptides thereof or gp-100 or peptides thereof.
- the chimeric receptor recognizes or binds to the MART-1 peptide, in particular epitopes M9-1 (TTAEEAAGI), M9-2 (AAGIGILTV), M10-3 (EAAGIGILTV), and M10-4 (AAGIGILTVI) (shown in single letter amino acid code) or gp-100 peptide epitopes.
- the chimeric receptor is provided as a recombinant DNA molecule comprising all or part of the T-cell receptor nucleic acid sequence and a vector.
- the nucleic acid sequences encoding the ⁇ and ⁇ chains of a T-cell receptor of the present invention may be placed in a single expression vector. Alternatively the ⁇ chain and the ⁇ chain may each be placed in a separate expression vector.
- Expression vectors suitable for use in the present invention may comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence.
- expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus, cytomegalovirus (CMV), SR ⁇ , MMLV, SV40 or housekeeping promoters such as phosphoglycerol kinase (PGK) and ⁇ actin.
- Additional preferred or required operational elements include, but are not limited to, leader sequences, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art that the correct combination of required or preferred expression control elements will depend on the host system chosen.
- the expression vector may contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system.
- additional elements include, but are not limited to, origins of replication and selectable markers and long terminal repeats (LTR) and internal ribosomal entry site (IRES).
- the expression vector may also include a leader peptide sequence. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods [Ausubel et al., (1987) in “Current Protocols in Molecular Biology”, John Wiley and Sons, New York, N.Y.] or commercially available.
- the chimeric receptor gene may comprise a first gene segment encoding the single chain Fv receptor (scFv) of a specific antibody, i.e., DNA sequences encoding the variable regions of the heavy and light chains (V H and V L , respectively) of the specific antibody, linked by a flexible linker, and a second gene segment which comprises a DNA sequence encoding partially or entirely the transmembrane and cytoplasmic, and optionally the extracellular, domains of a lymphocyte-triggering molecule corresponding to a lymphocyte receptor or part thereof.
- the scFvR design may be advantageous over the two-chain version of the receptor. It requires the expression of only one gene instead of the gene pair required for the cTCR, thereby providing simpler construction and transfection.
- the scFv domain may preferably be joined to the immune cell triggering molecule such that the scFv portion will be extracellular when the chimera is expressed. This is accomplished by joining the scFv either to the very end of the transmembrane portion opposite the cytoplasmic domain of the trigger molecule or by using a spacer which is either part of the endogenous extracellular portion of the triggering molecule or from other sources.
- the chimeric molecules of the present invention have the ability to confer on the immune cells on which they are expressed MHC nonrestricted antibody-type specificity. Thus, a continuous polypeptide of antigen binding and signal transducing properties can be produced and utilized as a targeting receptor on immune cells.
- the target cells are tumor cells and the scFv domain is derived from an antibody specific to an epitope expressed on the tumor cells. It is expected that such anti-tumor cytolysis can also be independent of exogenous supply of IL-2, thus providing a specific and safer means for adoptive immunotherapy.
- the single chain Fv chimeras can be made by joining the scFv domain with any receptor or co-receptor chain having a similar function to the disclosed molecules, e.g., derived from granulocytes, B lymphocytes, mast cells, macrophages, etc.
- the distinguishing features of desirable immune cell trigger molecules comprise the ability to be expressed autonomously (i.e., as a single chain), the ability to be fused to an extracellular domain such that the resultant chimera is expressed on the surface of an immune cell into which the corresponding gene was genetically introduced, and the ability to take part in signal transduction programs secondary to encounter with a target ligand.
- the specific expansion step amplifies an individual or a subpopulation of T cells whose endogenous TCR is directed to the strong antigen(s) used to expand the T cells.
- T cells which react with the antigen(s) are selected out and amplified from a mixed population of T cells originally obtained from the patient.
- the expanded lymphocytes are transduced with a chimeric receptor gene.
- These pre-selected, transduced T cells are introduced into a patient, and the patient is immunized with the strong antigen(s).
- This in vivo immunization step serves to activate the pre-selected adoptively transferred T cells and to target the lymphocytes to the cancer antigen through the chimeric receptor.
- peripheral blood lymphocytes In a preferred embodiment of the invention, patients undergo leukapheresis to obtain peripheral blood lymphocytes (PBL).
- the lymphocytes are separated from other cells.
- Various methods of separation are known to the artisan and can be utilized.
- One preferred separation technique employs centrifugation on a Ficoll cushion.
- the preferred host cells transformed with all or part of the chimeric receptor nucleic acid sequences may include JURKAT-cells, T-lymphocytes, peripheral blood cells such as peripheral blood lymphocytes (PBL) and peripheral blood mononuclear cells (PBMC), dendritic cells, monocytes, stem cells, natural killer (NK) cells or macrophages.
- NK cells lymphokine-activated killer cells (LAK), cytotoxic T cells, helper T cells, and the various subtypes of the above. These cells can execute their authentic natural function and can serve, in addition, as carriers of foreign genes designated for gene therapy, and the chimeric receptor shall serve in this case to direct the cells to their target.
- This approach can be applied also to anti-idiotypic vaccination by using helper T cells expressing chimeric receptors made of Fv of antiidiotypic antibodies.
- the cells are activated with one or more preselected antigens.
- Any strong antigen i.e. one that is capable of inducing proliferation of the adoptively transferred lymphocytes, may be utilized for the activation/selection step.
- the lymphocytes are preferably exposed to the strong antigen for greater than one hour in the case of proteins and virus or for at least 24 hours, preferably, continuously, for allogeneic cells as strong antigens.
- the strong antigen is provided up to a concentration of 1 millimolar when proteins, peptides or cellular components are used or at a ratio of one dual specific T-cell to 1-1000 infectious viral particles or between 1 and 100 allogeneic cells per each dual-specific T-cell.
- a combination of several stimuli may optionally be included in the activation/selection mixture.
- One preferred embodiment utilizes a donor's PBLs as an allogeneic agent. When donor PBLs are used, selection is carried out by co-culture of irradiated donor PBMC with patient PBMC at a ratio preferably with the range of 2:1 to 5:1.
- Transduction or introduction of foreign DNA into the immune cells may be carried out by any manner known in the art, such as, for example, microinjection, electroporation, transduction, retroviral transduction or transfection using DEAE-dextran, lipofection, calcium phosphate, particle bombardment mediated gene transfer or direct injection of nucleic acid sequences encoding the chimeric receptors or other procedures known to one skilled in the art [Sambrook et al. (1989) in “Molecular Cloning. A Laboratory Manual”, Cold Spring Harbor Press, Plainview, N.Y.].
- One preferred method of transduction follows the method described in Hwu, et al., (1993) J. Immunol. 150:4104-4115.
- One preferred method of transduction resuspends the lymphocyte preparation in a retroviral supernatant at a concentration range of 1 ⁇ 10 2 to 1 ⁇ 10 1 ° per ml, more preferably at a range of 1 ⁇ 10 4 to 1 ⁇ 10 8 , most preferably at a concentration of 1 ⁇ 10 6 .
- Transduction may preferably be followed by a selection step, such as for example using an antibiotic selection marker on the chimeric receptor gene construct, such as the neomycin resistance gene.
- the preselected transduced lymphocytes may be cultured for several days. Between days 14-21, it may be desirable to screen the cells for specific cytokine release against ovarian tumor antigens and/or assay for phenotype integrity. At this time, it may also be desirable to restimulate the lymphocyte population with the strong antigen. Restimulation using a strong antigen is preferably carried out at a similar concentration as used for the initial stimulation for a similar time period. If donor cells are used as the allogeneic agent, restimulation is preferably carried out at a ratio of 0.5:1 to 4:1, more preferably at a ratio of 1:1 to 2:1 (donor:patient). These cells can be directly reintroduced into the patient or can be frozen for future use, i.e. for subsequent administrations to this patient.
- patients Upon expansion of lymphocytes in IL-2 containing media, patients receive preselected transduced lymphocytes intravenously.
- the patient may also receive IL-2, preferably after the lymphocyte infusion.
- the IL-2 be provided at a dosage range of 1200 IU/kg to 1,200,000 IU/kg, more preferably at 120,000 IU/kg every 12 hours.
- patients may again receive preselected, transduced lymphocytes intravenously with or without similar doses of IL-2.
- Dual specificity lymphocytes are administered at a dosage range of 1 ⁇ 10 6 to 1 ⁇ 10 15 , more preferably 1 ⁇ 10 8 to 1 ⁇ 10 11 , most preferably 3 ⁇ 10 9 to 5 ⁇ 10 1 ° cells. Further details on dosage and frequency of cells are provided in U.S. Pat. No. 5,399,346, which is incorporated herein by reference, in toto.
- the present invention provides a method of inhibiting or preventing the growth of tumor cells by exposing tumor cells to the dual specificity lymphocytes provided herein.
- the dual specificity lymphocytes may be used for either prophylactic or therapeutic purposes.
- the dual specificity lymphocytes is provided in advance of any evidence or symptom in the mammal due to cancer, in particular, melanoma.
- the prophylactic use of the dual specificity lymphocytes serves to prevent or attenuate cancer, in particular melanoma, in a mammal.
- dual specificity lymphocytes are provided after the onset of the disease in the mammal.
- the therapeutic administration of the dual specificity lymphocytes serves to attenuate the disease.
- T-cell specificity may be redirected by combination of the in vitro transfer of the nucleic acid sequences encoding the tumor associated antigen specific T-cell receptors and selective expansion of the lymphocytes with one or more strong antigens.
- a heterogenous population of T-cells such as TIL
- TIL may be made more effective by conferring anti-tumor reactivity to non-specific T-cell populations within the TIL, and selective expansion of T lymphocytes to amplify T lymphocytes reactive with one or more pre-selected strong antigens.
- T-cells that can be modified to produce dual specificity lymphocytes include, but is not limited to, lymphocytes, cytotoxic T-lymphocytes, hematopoietic stem cells, monocytes, stem cells, peripheral blood and natural killer cells.
- T-cells can be genetically modified to express the tumor antigen specific T-cell receptors. Constructs containing all or parts of the nucleic acid sequences encoding the chimeric T-cell receptors may be introduced in T-lymphocytes by conventional methodology.
- such methods include, but are not limited to, calcium phosphate transfection, electroporations, lipofections, transduction by retroviruses, injection of DNA, particle bombardment and mediated gene transfer use of a retroviral vector, viral vectors, transduction by viral co-culturing with a producer cell line.
- the construct or constructs carrying the nucleic acid sequences encoding the chimeric T-cell receptors are introduced into the T-cells by transduction with viral supernatant or co-cultivation with a retroviral producer cell line.
- vectors examples include, but are not limited to, defective retroviral vectors, adenoviral vectors, vaccinia viral vectors, fowl pox viral vectors, or other viral vectors [Mulligan, R. C., (1993) Science 260:926-932].
- Eukaryotic expression vectors G1EN [Treisman, J., et al., Blood, 85:139; Morgan et al. (1992) Nucleic Acids Res. 20:1293-1299], LXSN [Miller, A. D., et al. Methods Enzymol., 217:581-599 (1993); Miller, A. D., et al.
- a retroviral vector for example a vector with the murine moloney leukemia viral LTR promoting transcription of the T-cells receptor genes is used.
- non-replicating retroviral vectors are used.
- the genes can be expressed using an internal housekeeping promoter, such as that from the phosphoglycerol kinase (PGK) gene.
- PGK phosphoglycerol kinase
- the ⁇ and ⁇ chains of the T-cell receptor may either be expressed on separate retroviral vectors, or on the same retroviral vector, separated by an internal ribosomal entry site (IRES) [Treisman, J., et al., Blood, 85:139; Morgan, R. A., et al., Nucleic Acids. Res., 20:1293-1299 (1992)].
- IRES internal ribosomal entry site
- T-lymphocytes include but are not limited to, peripheral blood cell lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes (TIL), or blood.
- lymphocytes can be isolated from the individual to be treated or from a donor by methods known in the art and cultured in vitro [Kawakami, Y. et al. (1989) J. Immunol. 142: 2453-3461].
- a single chain Fv receptor gene may be constructed and used as the chimeric receptor gene.
- the T-cells may be incubated with a retroviral producer cell line carrying retroviral expression vectors or with viral supernatant. Viability of the lymphocytes may be assessed by conventional methods, such as trypan blue dye exclusion assay.
- the genetically modified lymphocytes expressing the desired melanoma specific T-cell receptor may then be administered to a mammal, preferably a human, in need of such treatment in a therapeutically effective amount.
- TIL tumor infiltrating lymphocyte
- T-lymphocytes may be used as general guidelines for the doses or number of T-lymphocytes to be administered to mammal in need of such treatment.
- a range of about 1 ⁇ 10 10 to about 1 ⁇ 10 11 T-cells for each cycle of therapy may be administered in the methods provided herein.
- these antigen specific T-cells include but are not limited to, intravenously, intraperitoneally or intralesionally.
- Parameters that may be assessed to determine the efficacy of these transduced T-lymphocytes include, but are not limited to, production of immune cells in the mammal being treated or tumor regression. Conventional methods are used to assess these parameters.
- Such treatment can be given in conjunction with cytokines or gene modified cells [Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 75-90; Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 57-73] chemotherapy or active immunization therapies.
- cytokines or gene modified cells Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 75-90; Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 57-73
- chemotherapy or active immunization therapies One of skill in the art will appreciate that the exact treatment schedule and dosages, or amount of T-lymphocytes to be administered may need to be optimized for a given individual.
- This invention also relates to pharmacological compositions comprising the dual specificity lymphocytes.
- the formulations of the present invention both for veterinary and for human use, comprise each component individually or as a composition as described above, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic ingredients.
- the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the pharmaceutical art.
- compositions include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
- the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
- Formulations suitable for intravenous intramuscular, subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient.
- Such formulations may be conveniently prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile.
- physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like
- physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like
- pH compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like
- These may be present in unit or multi-dose containers, for example, sealed ampoules or vials.
- the formulations of the present invention may incorporate a stabilizer.
- Illustrative stabilizers are polyethylene glycol, proteins, saccharide, amino acids, inorganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part by weight of each component or the composition. If two or more stabilizers are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and pH. The specific osmotic pressure of such aqueous solutions is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8-1.2. The pH of the aqueous solution is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8. In formulating each component separately or as a composition of the present invention, anti-adsorption agent may be used.
- Controlled release preparations may be achieved through the use of polymer to complex or absorb the cells or their derivatives.
- the controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release.
- appropriate macromolecules for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate
- Another possible method to control the duration of action by controlled-release preparations is to incorporate the 9-cis-retinoic acid or derivatives thereof alone or in combination with antineoplastic agents thereof into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
- a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers.
- microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
- the component may be combined with typical carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
- typical carriers such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
- compositions or of each individual component of the present invention may be for either a prophylactic or therapeutic purpose.
- the methods and compositions used herein may be used alone in prophylactic or therapeutic uses or in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of cancer. Alternatively the methods and compositions described herein may be used as adjunct therapy. Veterinary uses are also intended to be encompassed by this invention.
- chimeric receptors against ovarian cancer were found to be functional in primary T cells in vitro and in vivo [Hwu, P., et al. J. Exp. Med., 178:361-366, 1993; Hwu, P., et al., Cancer Res., 55:3369-3373, 1995].
- the effects of treating eight patients with advanced ovarian cancer with T cells transduced with chimeric receptor genes derived from a monoclonal antibody against ovarian cancer, MOv-18 alone, and without any specificity were observed.
- TIL Tumor-infiltrating lymphocytes
- PBL peripheral blood lymphocytes
- MOv-18 chimeric receptor gene MOv-7
- FIG. 2 shows the percentage of circulating transduced cells during the course of the treatment after MOv-PBL infusion.
- the PBMC from day 5 were cultured in G418 (for neomycin resistant selection), anti-CD3, and IL-2. After 17 days, the culture was highly enriched for reisolated MOv-PBL (69% positive for gene) that were capable of specifically producing large amounts of cytokine in response to ovarian tumor cells. As measured by IFN- ⁇ release (pg/ml), Table 1 shows that MOv-PBL retained their ability to recognize tumor after adoptive transfer.
- the NV PBL group did not result in IGROV or melanoma reactivity.
- the NV PBL and G418 group also did not result in significant IGROV, 888 mel, or 1300 mel reactivity.
- anti-allogeneic mouse (C57BL/6) T cells were raised in a mixed lymphocyte reaction (MLR) for 7 days and restimulated for 6 additional days.
- MLR mixed lymphocyte reaction
- Thy 1.1+ alloreactive (H2-b anti-H2-d) T cells were generated and expanded and 1 ⁇ 10 7 cells were adoptively transferred into congenic C57BL/6 mice (Thy 1.2) by intravenous injection.
- the C57BL/6 mice were immunized with allogeneic antigen presenting cells from BALB/c mice on days 2, 5, and 8 after transfer.
- stimulators for example, either allogeneic splenocytes or allogeneic dendritic cells (DC) were used to immunize the mice.
- Stimulators are strong antigenic agents which activate responder cells, for example lymphocytes.
- lymphocytes There were 3 mice per condition group. Tissues (spleen, lung, and blood) were harvested on day 11 and Thy 1.1 cells were quantified following staining and fluorescence-activated cell sorter (FACS) analysis. The percent of Thy 1.1 cells in tissue was measured by comparing those immunized with allogeneic splenocytes and allogeneic DC.
- FACS fluorescence-activated cell sorter
- Adoptively transferred, cultured alloreactive T cells were found to expand in vivo following immunization with allogeneic antigen presenting cells and increased the survival of in vitro-cultured, adoptively transferred allo-reactive T cells upon immunization with allogeneic cells ( FIGS. 3A and 3B ).
- mice T cells (2 ⁇ 10 7 ) were raised in a mixed leukocyte reaction (MLR) in 24 well plates and 10 CU/ml IL-2 with restimulation on day 7.
- G418 0.5 mg/ml was added for 6 days until day 13 and assayed for MOv-'y expression and IFN- ⁇ secretion in response to various target cells.
- Table 2 and FIG. 4 show that dual specificity T cells expressing chimeric MOv- ⁇ with significant anti-allogeneic and anti-FBP activity as measured by IFN- ⁇ (pg/ml) was generated.
- mice received 1 ⁇ 10 7 dual specificity allogeneic/MOv- ⁇ T cells followed by subcutaneous immunization with 5 ⁇ 10 7 allogeneic splenocytes from donor mice 2 days later. Seven days after immunization, mice were challenged with 2 ⁇ 10 5 24JK-FBP ovarian cancer tumor cells subcutaneously.
- the 24JK is a clone from the 3-methylcholanthrene-induced, poorly immunogenic MCA 102 murine sarcoma, where 24JK-FBP is 24JK transduced with the folate binding protein (FBP) gene, which is expressed highly on ovarian adenocarcinomas and MOv- ⁇ is a mAb that binds FBP.
- FBP folate binding protein
- FIG. 5 shows that in vivo immunization with allogeneic splenocytes from donor mice, in combination with administration of dual specificity T cells protected mice much more significantly than T cells alone. Specifically, the combined conditions result in 100% tumor-free mice while mice infused with dual specificity T cells alone resulted in 25% tumor-free mice.
- mice In order to determine whether the combination of adoptively transferred dual specificity T cells and immunization with allogeneic cells can inhibit established subcutaneous tumors, 3 RAG-1 immunodeficient knock out mice per condition were injected on day 0 with 2 ⁇ 10 5 tumor cells, specifically, 24JK and 24JK-FBP tumor cells. On day 3, mice received either 1 ⁇ 10 7 dual specificity T cells, 1 ⁇ 10 7 non-transduced (NV) T cells, or no treatment. Subcutaneous immunization with 5 ⁇ 10 7 allogeneic splenocytes was performed on days 5, 8, and 11. On day 15, one mouse per group having a middle sized tumor was sacrificed in order to determine the effect of immunization on transferred T cell numbers.
- NV non-transduced
- FIG. 6 shows that mice injected with 24JK-FBP tumor cells followed by transduced dual specificity T cells and immunization or boost, resulted in the smallest tumor size throughout the time course of 29 days.
- cultured cells were transduced with MOv-'y supernatant during centrifugation at 1000 g (2700 rpm in Sorvall tabletop centrifuge for 1 hour) in the presence of 8 ⁇ g/ml polybrene, a polycation which aids in retroviral infection.
- On days 18-22 cells were incubated with 0.5 mg/ml G418 (Geneticin; Life Technologies) per day for neomycin selection.
- G418 Geneticin; Life Technologies
- cells were restimulated with donor 269 PBMC as above.
- the bulk population was assayed and cloned at 1 cell/well using standard surgery branch (SB) method with OKT3 stimulation and PBMC from another donor.
- SB standard surgery branch
- the clones were characterized.
- FIGS. 8A-8F FACS analysis
- FIGS. 8A-8C represent the phenotype for the bulk population of patient 399 anti-269
- FIGS. 8D-8F represent the phenotype for the bulk population of patient 363 anti-269.
- FIGS. 8A and 8D show the control results using non-specific IgG2a; FIGS.
- FIGS. 8B and 8E describe the CD4 and/or CD8 phenotype of the population of cells; and FIGS. 8C and 8F show the shift of the MOv antibody-stained cells which represents the presence of the ovarian cancer (MOv)-specific receptor on T cells.
- MOv ovarian cancer
- PBMC from patient 410 were used to generate and characterize dual specificity T cells.
- 5 ⁇ 10 7 PBMC from 410 were cultured in the presence of 2 ⁇ 10 6 responders irradiated allogeneic PBMC/well from donor 556 (AIM-V/5% human serum; 100 CU IL-2/ml; in 24 well plates).
- PBMC from 410 were transduced with MOv-y supernatant supplemented with 8 ⁇ g/ml polybrene. Plates were centrifuged at 1000 g or 2700 rpm.
- 10A-10B and Table 3 describe the phenotypic characteristic of the bulk population of patient 410 anti-556 donor cells.
- the majority of cells are CD4 helper T cells and were found to be reactive against IGROV. Therefore, dual specificity human T cells can be grown to recognize both allogeneic targets as well as tumor.
- Table 4 shows GM-CSF secretion from ten of the most reactive transduced dual specificity PBMC 410 clones. These results confirm that each clone is both alloreactive as demonstrated by the high GM-CSF release in response to PBMC 556 donor and specific for ovarian cancer as demonstrated by the high GM-CSF secretion in response to IGROV.
- 11A-11J show the phenotype characterizations of representative selected clones 1, 3, 5, 8, and 9. Although there is some variation in whether the clone is CD4+, CD8+, or both CD4+/CD8+, all clones recognize the presence of the ovarian cancer specific receptor on T cells.
- the type of stimulator cells, the stimulator:responder ratio in MLR, IL-2 concentration, and conditions for restimulation must be optimized. Therefore, 2 ⁇ 10 6 fresh responder PBMC from a normal donor were incubated in wells of a 24 well plate with a stimulator comprising one of irradiated allogeneic PBMC, B cells, or DC at the following stimulator to responder ratios: 5:1, 1.5:1, 1:2, 1:6, 1:20, and 1:60 in AIM-V/5% human serum; 100 CU IL-2/ml).
- FIGS. 12A-12D show growth curves following stimulation with various allogeneic cell types and at various stimulator:responder ratios.
- FIG. 12D is the control responder without stimulators.
- Table 5 describes the phenotype of T cell cultures generated from a variety of APC and stimulator to responder ratios on day 17.
- Tables 6-9 show the results of functional assays of cells on day 17 after stimulation for the various APC and stimulator: responder ratios, where the different ratios were performed in duplicates. Allogeneic PBMC were determined to be good stimulators for MLR, and result in high levels of expansion when using stimulator:responder ratios ranging from 1.5:1 to 5:1. Functional assays demonstrated that transduced cells generated from PBMC stimulators were capable of recognizing allogeneic and tumor targets.
- FIGS. 13A-13D show the number of transduced cells upon further stimulation.
- T cells from cryopreserved cells were generated using PBMC at a ratio of 1:1 (2 ⁇ 10 6 stimulator to 2 ⁇ 10 6 responder/well), in the presence of various IL-2 concentrations.
- T cells were transduced with MOv- ⁇ and selected in 0.5 mg/ml G418 for 5 days. Proliferation and reactivity against allogeneic and tumor targets were determined.
- FIG. 14 shows T cell growth in MLR with various IL-2 concentrations in CU/ml. Results indicate that as the concentration of IL-2 increases, the number of T cells generated also increases.
- Table 10 The phenotypic characteristics of T cell cultures generated from a variety of IL-2 concentrations is depicted in Table 10.
- T cells are predominantly CD3-1- and then CD4+.
- Table 11 the function of MOv- ⁇ transduced alloreactive T cells grown in a variety of IL-2 concentrations as measured by IFN- ⁇ release (pg/ml) demonstrates that 50 CU IL-2/ml provides good expansion, as well as a high level of reactivity against both allogeneic and tumor targets.
- Serum-free AIM-V medium is supplemented with penicillin G (50 units/ml), and L-glutamine (292-584 mg/ml, 2 mM), as well as IL-2 (100 CU/ml). If necessary, AIM-V medium can also be supplemented with 1-10% human serum (type AB heat inactivated at 56° C. for 30 minutes).
- PBL is isolated by leukapheresis. Lymphocytes are separated by centrifugation 1000 g (2700 rpm) on a Ficoll cushion. PBL is subjected to multiple exposures of retroviral supernatant, for up to 3 days. The PBL is then selected for 5 days in 0.5 mg/ml of the neomycin analog G418 (Geneticin; Gibco; Grand Island, N.Y.). Following G418 selection, PBL is expanded in AIM V media with 100 CU/ml IL-2. If necessary, AIM V is supplemented with 1-10% human AB serum. The exact days stated below is an approximation of what is expected for PBL transduction.
- the PSL are screened for specific cytokine release against the ovarian tumor cell line IGROV-1, and phenotype by FACS analysis. Aliquot 5 ⁇ 10 6 transduced, selected PBL for PCR analysis. Send samples for S+L-assay for retrovirus.
- the patient PBMC are restimulated with irradiated donor PBMC at a ratio of 1:1 to 2:1 (donor:patient).
- the density of PBL is maintained between 1 ⁇ 10 6 and 2.5 ⁇ 10 6 PBL/ml. Once PBL have begun to grow, the cultures are assessed for growth every 3-4 days to insure that they do not increase beyond 2.5 ⁇ 10 6 /ml.
- PBL are removed from the tissue culture plates or flasks and cultured further in Fenwal PL732 cell culture bags. These bags have a 1-liter capacity, but normally 500 mls medium are the maximum used in each bag. PL732 bags are gas permeable, but impermeable to fluids. Thus, oxygen and CO 2 are freely exchanged while tissue culture medium and cells are maintained inside. Using an inverted syringe (plunger removed), suspended by a clamp on a ring stand, connect the needle-adapter end of the syringe to the female-luer port of the 1 liter PL732 bag.
- PL732 bags are advantageous in that access to the medium containing cells is limited to injection sites and sterile tubing ports, both of which can be maintained aseptically.
- PBL cell counts are done every 3-4 days.
- the PL732 bags containing medium and PBL are “split” 1:2 or 1:3 to reduce the PBL concentration to a level of 1 ⁇ 10 6 /ml or a bit above.
- a 1:2 split of cells at 2.0 ⁇ 10 6 /ml involves transferring 500 mls of medium (containing PBL) to a new 3 liter PL732 bag and adding 500 mls of AIM-V containing IL-2 to bring the total volume up to 1000 ml.
- the AIM-V being added to the 3 liter PL732 bag is transferred from a 10 liter STAK PACK of AIM-V medium (GIBCO; Life Technologies, Grand Island, N.Y.) using a sterile Solution transfer set, Life-adapter set, 8′′ Interconnecting jumper tube, and a Fluid fill/weigh unit.
- At least 4 ⁇ 10 9 cells (generally)1 ⁇ 10 1 ° may be removed for bulk freezing in a bag, keeping at least 4 ⁇ 10 9 PBL in culture in order to generate cells for treating the patient.
- the PBL might be removed a week before treatment.
- PBL are commonly used for treatment after 14-45 days in culture.
- PBL doubling time is 1.5 to 3 days.
- PBL cultures are generally split to new bags containing fresh medium every 3-5 days. Fungizone is left out of the last passage of cells in bags to minimize adverse effects on the patients.
- a sample is collected from the last passage of PBL for microbiology tests; this should be done 2-5 days prior to the beginning of PBL therapy. The test takes 2 days.
- the bags are then harvested for treatment using an automated process of cell harvesting as described by Muul, et al. J. Immunol. Methods 101:171, 1987).
- PBL are infused in a volume of 200-300 ml of saline supplemented with 50 ml of 25% human albumin (Alpha Therapeutic Co.). Cells are infused over 30-60 minutes through a central venous catheter. Patients receiving dual specificity cells are immunized with donor PBMC 1 and 8 days after each cell infusion. Each immunization is performed with up to 5 ⁇ 10 9 donor PBMC, depending on the number of cells available, administered subcutaneously in the thighs at a concentration of up to 7 ⁇ 10 8 PBMC per ml of injectate.
- Cryopreserved, transduced PBL can be thawed for subsequent cycles or courses of therapy. If necessary, repeat transduction may be performed on either fresh PBL or cryopreserved, non-transduced PBL.
- IL-2 is administered at a dose of 120,000 CU/kg as an intravenous bolus over a 15 minute period every twelve hours beginning on the day of PBL administration and continuing for up to eight doses. Doses may be skipped depending on patient tolerance. Also, if patients reach Grade III or IV toxicity (not easily reversed) due to IL-2 except for the reversible Grade III toxicities common to IL-2 such as diarrhea, nausea, vomiting, hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and laboratory changes as detailed in Table 12, doses are not administered. If this toxicity is easily reversed by supportive measures then additional doses are given. No more than 12 doses of IL-2 is ever administered.
- IL-2 (Chiron), NSC #373364, is provided as a 5 mL vial containing 1.3 mg of protein as a lyophilized powder cake, with mannitol 50 mg and Sodium Dodecyl Sulfate 130 ⁇ g per milligram of protein.
- the vial is reconstituted with 2.0 mL of Sterile Water for Injection, USP, and the resultant concentration is 10.8 million IU/ml or 1.8 million CU/ml. Diluent should be directed against the side of the vial to avoid excess foaming. Contents are gently swirled, not shaken, until completely dissolved. Since vials contain no preservative, reconstituted solution should be used with 8 hours.
- Intact vials are stored in the refrigerator (2-8° C.) protected from light. Each vial bears an expiration date.
- Reconstituted IL-2 is further diluted with 50 mL of 5% Human Serum Albumin (HSA).
- HSA Human Serum Albumin
- the HSA is added to the diluent prior to the addition of recombinant IL-2.
- Dilutions of the reconstituted solution over a 1000-fold range i.e., 1 mg/mL to 1 ⁇ g/mL
- Reconstituted solutions are not mixed with saline-containing solutions.
- IL-2 is chemically stable for 48 hours at refrigerated and room temperatures, 2-30° C.
- All patients receiving IL-2 also receive concomitant medications to relieve side effects as in all previous high-dose IL-2 protocols.
- the following concomitant medication begins the evening before the first dose of IL-2 and continues throughout the entire cycle of treatment: acetaminophen (650 mg every 4 hr), indomethacin (50-75 mg every 6-8 hr), and ranitidine (150 mg every 12 hr).
- Patients receive intravenous meperidine (25 to 50 mg) to control chills when they occur, although chills are unusual after the first one to two doses of IL-2.
- Ondansetron, droperidol, or scopolamine is available as needed for the treatment of nausea during treatment. Steroids are not used in these patients and if steroids are required then the patient should be taken off protocol therapy.
- cultures may be expanded using 1000 CU/ml IL-2 or the “Rapid Expansion Protocol” (REP) as described below: MOv-transduced PBL are counted and the specified number is used (Table 13). In the REP cycle immediately preceding infusion, 1.25 mg/ml Fungizone and 1 ml/L Cipro are added on day 8, and AIM V media is used.
- REP Rapid Expansion Protocol
- PBMC On day 0 PBMC are thawed, washed twice in AIM V media, resuspended in complete media (CM; RPMI media) and irradiated (340 Gy) as described above. PBMC and OKT3 are added to CM, mixed well, and aliquots are transferred to tissue culture flasks. Viable cells are added last. Flasks are incubated upright at 37° C. in 5% CO 2 .
- IL-2 is added to a final concentration of 50 CU/ml.
- IL-2 is added to a final concentration of 50 CU/ml. Cells are split if density exceeds 1.5 ⁇ 10 6 cells/ml.
- a complete response is defined as the disappearance of all clinical evidence of disease that lasts at least four weeks.
- Partial response is defined as a 50% or greater decrease in the sum of the products of the maximal perpendicular diameter of all measurable lesions for at least four weeks with no appearance of new lesions or increase in any lesions.
- a minor response is defined as a 25-49% decrease in the sum of the products of the maximal perpendicular diameters of all measurable lesions but no appearance of new lesions and no increase in any lesion.
- Any patient with less than a minor response will be considered a nonresponder.
- the appearance of a new lesion or a greater than 25% increase in the product of perpendicular diameters of any prior lesion following a partial or complete response will be considered a relapse.
- Retroviral supernatant containing the MOv- ⁇ chimeric receptor gene was used for lymphocyte transductions (Retroviral supernatant to be produced by Somatix, Inc, Alameda Calif.).
- the MFG-S retroviral vector and the ⁇ -CRIP packaging cell line were used (Danos, O. and R. C. Mulligan. Proc. Natl. Acad. Sci. U.S.A., 85:6460-6464, 1988), similar to that approved for use in ongoing clinical trials (Jaffee, et al. Cancer Res., 53:2221-2226, 1993).
- Moloney murine leukemia virus (MoMLV) long terminal repeat (LTR) sequences were used to generate both a full length viral RNA necessary for the generation of viral particles and a subgenomic mRNA analogous to the MO-MuLV envelope RNA, which is responsible for the expression of the MOv- ⁇ gene ( FIG. 15 ).
- the vector retained sequences in both the viral gag region shown to improve the encapsidation of viral RNA and the normal viral 5′ and 3′ splice sites necessary for generation of the subgenomic RNA.
- the T-CRIP cell line provided the viral proteins necessary for encapsidation of recombinant retroviral genomes into infectious particles.
- the expression of the relevant viral gene products in ⁇ -CRIP cells is accomplished in a manner designed to prevent the encapsidation and mobilization of the RNA molecules encoding the viral gene products. This makes possible the generation of stocks of replication-deficient recombinant virus, free of replication-competent virus.
- High titer stocks of recombinant virus suitable for clinical use were generated from cultures derived from the working cell bank (WBC) propagated in a closed-loop perfusion system designed for the mass culture of anchorage dependent cells.
- the system allowed the culture medium to be monitored for perfusion rate, oxygen levels, and pH, permitting the growth and maintenance of large numbers of cells in a minimal volume of medium.
- WBC working cell bank
- approximately 5 ⁇ 10 10 cells were cultured in a single vessel which minimized the risk of contamination from handling multiple flasks, and additionally ensured a consistent lot of recombinant virus.
- a vial of the WCB of the producing cell line was thawed and expanded in culture to generate sufficient numbers of cells to seed the bioreactor.
- the cells were re-tested for sterility and mycoplasma contamination.
- the system was then seeded and monitored until the optimal cell density is achieved. At this point, fresh culture supernatant was collected, filtered, and stored in frozen aliquots for quality control and safety testing as required for FDA approval, followed by clinical use.
Abstract
The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy.
Description
- The field of the present invention relates generally to compositions and methods for the treatment or prevention of diseases in mammals. More specifically, this invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and/or chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens and to preventative, diagnostic and therapeutic applications which employ these lymphocytes.
- Classic modalities for the treatment of diseases such as human cancers, autoimmune diseases, viral, bacterial, parasitic and fungal diseases include surgery, radiation chemotherapy, antibiotics or combination therapies. However, these therapies are not effective against a majority of these diseases. Alternate therapies for preventing or treating human diseases are greatly needed. In the past decade immunotherapy and gene therapy utilizing T-lymphocytes have emerged as new and promising methods for treating human disease, in particular human cancers.
- The T cell receptor for antigen (TCR) is responsible for the recognition of antigen associated with the major histocompatibility complex (MHC). The TCR expressed on the surface of T cells is associated with an invariant structure, CD3. CD3 is assumed to be responsible for intracellular signaling following occupancy of the TCR by ligand.
- The T cell receptor for antigen-CD3 complex (TCR/CD3) recognizes antigenic peptides that are presented to it by the proteins of the major histocompatibility complex (MHC). Complexes of MHC and peptide are expressed on the surface of antigen presenting cells and other T cell targets. Stimulation of the TCR/CD3 complex results in activation of the T cell and a consequent antigen-specific immune response. The TCR/CD3 complex plays a central role in the effector function and regulation of the immune system.
- Two forms of T cell receptor for antigen are expressed on the surface of T cells. These contain either α/β heterodimers or γ/δ heterodimers. T cells are capable of rearranging the genes that encode the α, β, γ and δ chains of the T cell receptor. T cell receptor gene rearrangements are analogous to those that produce functional immunoglobulins in B cells and the presence of multiple variable and joining regions in the genome allows the generation of T cell receptors with a diverse range of binding specificities. Each α/β or γ/δ heterodimer is expressed on the surface of the T cell in association with four invariant peptides. These are the γ, δ and ε subunits of the CD3 complex and the zeta chain. The CD3 γ, δ and ε polypeptides are encoded by three members of the immunoglobulin supergene family and are found in a cluster on
human chromosome 11 ormurine chromosome 9. The zeta chain gene is found separately from other TCR and CD3 genes onchromosome 1 in both the mouse and human. Murine T cells are able to generate a receptor-associated η chain through alternative splicing of the zeta mRNA transcript. The CD3 chains and the zeta subunit do not show variability, and are not involved directly in antigen recognition. - All the components of the T cell receptor are membrane proteins and consist of a leader sequence, externally-disposed N-terminal extracellular domains, a single membrane-spanning domain, and cytoplasmic tails. The α, β, γ and δ antigen-binding polypeptides are glycoproteins. The zeta chain has a relatively short ectodomain of only nine amino acids and a long cytoplasmic tail of approximately 110 amino acids. Most T cell receptor α/β heterodimers are covalently linked through disulphide bonds, but many γδ receptors associate with one another non-covalently. The zeta chain quantitatively forms either disulphide-linked ζ-η heterodimers or zeta-zeta homodimers.
- Another example of a type of receptor on cells of the immune system is the Fc receptor. The interaction of antibody-antigen complexes with cells of the immune system results in a wide array of responses, ranging from effector functions such as antibody-dependent cytotoxicity, mast cell degranulation, and phagocytosis to immunomodulatory signals such as regulating lymphocyte proliferation, phagocytosis and target cell lysis. All these interactions are initiated through the binding of the Fc domain of antibodies or immune complexes to specialized cell surface receptors on hematopoietic cells. It is now well established that the diversity of cellular responses triggered by antibodies and immune complexes results from the structural heterogeneity of Fc receptors (FcRs).
- FcRs are defined by their specificity for immunoglobulin isotypes. Fc receptors for IgG are referred to as FcγR, for IgE as FcεR, for IgA as FcαR, etc. Structurally distinct receptors are distinguished by a Roman numeral, based on historical precedent. Three groups of FcγRs, designated FcγRI, FcγRII, and FcγRIII are now recognized. Two groups of FcεR have been defined; these are referred to as FcεRI and FcεRII. Structurally related although distinct genes within a group are denoted by A, B, C. Finally, the protein subunit is given a Greek letter, such as FcγRIIIAα, FcγRIIIAγ.
- Considerable progress has recently been made in defining the heterogeneity for IgG and IgE Fc receptors (FcγR, FcεR) through their molecular cloning. These studies make it apparent that Fc receptors share structurally related ligand binding domains, but differ in their transmembrane and intracellular domains which presumably mediate intracellular signaling. Thus, specific FcγRs on different cells mediate different cellular responses upon interaction with an immune complex. The structural analysis of the FcγRs and FcεRI has also revealed at least one common subunit among some of these receptors. This common subunit is the γ subunit, which is similar to the ζ or η chain of the TCR/CD3, and is involved in the signal transduction of the FcγRIII and FcεRI.
- The low affinity receptor for IgG (FcγRIIIA), is composed of the ligand binding CD16α (FcγRIIIAα) polypeptide associated with the γ chain (FcγRIIIAγ). The CD16 polypeptide appears as membrane anchored form in polymorphonuclear cells and as transmembrane form (CD16™) in NK. The FcγRIIIA serves as a triggering molecule for NK cells.
- Another type of immune cell receptor is the IL-2 receptor. This receptor is composed of three chains, the α chain (p55), the β chain (p75) and the γ chain. When stimulated by IL-2, lymphocytes undergo proliferation and activation.
- Antigen-specific effector lymphocytes, such as tumor specific T cells (Tc), are very rare, individual-specific, limited in their recognition spectrum and difficult to obtain against most malignancies. Antibodies, on the other hand, are readily obtainable, more easily derived, have wider spectrum and are not individual-specific. The major problem of applying specific antibodies for cancer immunotherapy lies in the inability of sufficient amounts of monoclonal antibodies (mAb) to reach large areas within solid tumors. In practice, many clinical attempts to recruit the humoral or cellular arms of the immune system for passive anti-tumor immunotherapy have not fulfilled expectations. While it has been possible to obtain anti-tumor antibodies, their therapeutic use has been limited so far to blood-borne tumors [Lowder, J. N. et al. Cancer Surv. 4:359-375 (1985); Waldmann, T. A. Science 252:1657-1662 (1991)] primarily because solid tumors are inaccessible to sufficient amounts of antibodies [Jain, R. K. J. Natl. Cancer Inst. 81:64-66 (1989)]. The use of effector lymphocytes in adoptive immunotherapy, although effective in selected solid tumors, suffers on the other hand, from a lack of specificity (such as in the case of lymphokine-activated killer cells (LAK cells) [Mule, J. J. et al. Science 225:1487-1489 (1984)] which are mainly NK cells) or from the difficulty in recruiting tumor-infiltrating lymphocytes (TILs) and expanding such specific T cells for most malignancies [Rosenberg, S. A. et al. Science 233:1318-1321 (1986)]. Yet, the observations that TILs can be obtained in melanoma and renal cell carcinoma tumors, that they can be effective in selected patients and that foreign genes can function in these cells [Rosenberg, S. A. J. Clin. Oncol. 10:180-199 (1992)] demonstrate the therapeutic potential embodied in these cells.
- A strategy which has been developed (European Published Patent Application No. 0340793) allows one to combine the advantage of the antibody's specificity with the homing, tissue penetration, cytokine production and target-cell destruction of T lymphocytes and to extend, by ex vivo genetic manipulations, the spectrum of anti-tumor specificity of T cells. Chimeric T cell receptor (cTCR) genes composed of the variable region domain (Fv) of an antibody molecule and the constant region domain of the antigen-binding TCR chains, i.e., the α/β or γ/δ chains have been expressed in T cells and found to be functionally active. Adoptive immunotherapies using tumor infiltrating lymphocytes and IL-2 have been developed for some cancers. These therapies have resulted in significant long-term responses in some patients with melanoma.
- In an effort to broaden the applicability of adoptive immunotherapy to common cancers, such as, for example, ovarian, breast and colon cancer treatments that redirect the immune reactivity of lymphocytes to antigens recognized by monoclonal antibodies have been developed. To do this, retroviral vectors that encode chimeric receptor genes consisting of the variable regions of a monoclonal antibody joined to the transmembraneous and cytoplasmic domains of a T-cell receptor (TCR) signaling chain have been utilized. Using this approach, the safety of the administration of these chimeric receptor-transduced lymphocytes has been demonstrated. However, a need for improving the effectiveness of the chimeric receptor-transduced lymphocytes exists.
- Thus, one object of the present invention is to produce an activated chimeric receptor-transduced lymphocyte capable of binding to and obliterating cancer cells.
- One particular object of the present invention is to increase the effectiveness of adoptive immunotherapy by increasing the persistence and/or activity of adoptively transferred T cells by activating a pre-selected population of adoptively transferred lymphocytes with in vivo immunization.
- Another objective of the invention is to create dual specific T cells by genetic modification so that each individual T cell is reactive with both a strong antigen, such as, for example an alloantigen or other foreign agent, and the tumor. The strong antigen is used both to expand and activate the cells in vitro and in vivo.
- The present invention relates to a composition comprising a population of T cells transduced with a chimeric receptor gene and pre-selected for reactivity with a strong antigen. Another embodiment of the present invention comprises a lymphocyte having a TCR directed to a specific strong antigen and a chimeric T-cell receptor directed to a tumor antigen, wherein the lymphocyte has been activated in vivo by the strong antigen. Such cells exhibit strong anti-tumor response and provide a recipient of such cells with a protection from tumor challenge, i.e. prophylactic response, and an anti-tumor treatment.
- The method of treating a patient with therapeutically-activated dual-specificity lymphocytes comprises the steps of expanding a patient's lymphocytes with one or more specific strong antigens ex vivo, transducing the lymphocytes with a chimeric receptor gene, introducing the transduced lymphocytes into the patient and immunizing the patient with the strong antigents) in vivo. A preferred embodiment of the present method utilizes an alloantigen as the strong antigen. Another preferred embodiment utilizes a virus or other foreign antigen as the strong antigen.
- The present invention also relates to a method of treating a patient with dual specificity lymphocytes having reactivity to one or more pre-selected strong antigens comprising the steps of administering an effective amount of such lymphocytes to a patient and immunizing the patient with the strong antigen.
- The present invention relates to activated dual specific lymphocytes containing chimeric genes suitable to endow lymphocyte cells with antibody-type specificity and T-cell receptors specific for one or more pre-selected strong antigens. Various types of lymphocytes are suitable, for example, natural killer cells, helper T cells, suppressor T cells, cytotoxic T cells, lymphokine activated cells, subtypes thereof and any other cell type which can express chimeric receptor chain.
- The present invention further relates to pharmaceutical, prophylactic and curative compositions containing an effective quantity of such cells.
-
FIG. 1 shows a model of the dual-specific T cell created by genetic modification such that each individual T cell has specificity for both the strong antigen/immunogen and tumor. The chimeric receptor enables tumor recognition and comprises single-chain antibody variable regions (scFv) connected to TCR signaling chains, such as the γ chain of the Fc receptor. -
FIG. 2 shows the results of treating 8 advanced ovarian cancer patients with MOv-PBL infusion. Specifically, treatment was measured by the percentage of circulating MOv-γ transduced lymphocyte cells following MOv-PBL infusion. -
FIGS. 3A and 3B show the in vivo effects of allogeneic immunization of adoptively transferred T cells in mice spleen, lung, and blood upon immunization with allo-splenocytes (A) and alto-DC (dendritic cells; B) as a measure of Thy 1.1 cells in tissue. -
FIG. 4 shows the phenotypic results of dual specific mouse T cells, where these T cells express the chimeric MOv-y. -
FIG. 5 shows that mice are protected against tumor challenge when infused with dual specific T cells followed by immunization with allogeneic splenocytes. -
FIG. 6 shows a time course graph of the adoptive transfer of dual specific T cells followed by immunization treatment of established subcutaneous tumor in immunodeficient mice. The results show that dual specific T cells inhibit tumor growth and that the effect is augmented by immunization. -
FIG. 7 demonstrates that dual specific MOv-γ transduced human T cells capable of recognizing both allogeneic cells and ovarian cancer cells can be generated in vitro by using PBMC from patients (363 and 399), transducing with MOv-y, and stimulating with PBMC from donor (269). The graph shows that transduced and non transduced cells released GM-CSF in response todonor 269 PBMC. In addition, transduced patient (363 and 399) cells released significant amounts of GM-CSF in response to IGROV, indicating that these transduced T cells were allogeneic- and IGROV-reactive. -
FIGS. 8A-8F shows the phenotypic results of the bulk population of T cells frompatient 399 anti-269 (A-C) and ofpatient 363 anti-269 (D-F), where 8C and 8F demonstrate that the T cells express the chimeric MOv-γ receptor. -
FIG. 9 shows the functional assay results from bulk MOv-γ transduced T cells of patient 410, where T cells are both allo- and IGROV-reactive as measured by GM-CSF release (pg/ml). -
FIGS. 10A-B show the phenotypic results of bulk MOv-y transduced T cells of patient 410 (anti-556 donor), where the T cells are primarily CD4+ and do in fact express the chimeric MOv-γ receptor. -
FIGS. 11A-11J show the phenotypic results of individual daughter clones from the bulk MOv-γ transduced T cells of patient 410 (anti-556 donor).FIGS. 11A-11E show that the T cells express the chimeric MOv-γ receptor, as demonstrated by the shift in peak on the X-axis.FIGS. 11F-11J demonstrate by FACS whether the clone is CD4 or CD8. -
FIGS. 12A-12D show growth curve analysis of responder cells transduced with dual specific T cells following stimulation with various allogeneic cell types (PBMC, DC, or B cells) and control at varying stimulator:responder ratios. -
FIGS. 13A-13D show growth curve analysis of responder cells transduced with dual specific T cells following restimulation with various allogeneic cell types (PBMC, DC, or B cells) and control at varying stimulator:responder ratios. -
FIG. 14 shows growth curve analysis of alloreactive T cells in MLR with various concentrations of IL-2. -
FIG. 15 shows the MFG-MOv-γ-I-N retroviral vector. - For the purpose of a more complete understanding of the invention, the following definitions are described herein. Nucleic acid sequences include, but are not limited to, DNA, RNA or cDNA. Substantially homologous as used herein refers to substantial correspondence between the nucleic acid sequence for the V-J or V-D-J junctional sequences for the α and β chains of the tumor antigen specific T-cell receptors provided herein and that of any other nucleic acid sequence. By way of example, substantially homologous means about 50-100% homology, preferably by about 70-100% homology, and most preferably about 90-100% homology between the nucleic acid sequences and that of any other nucleic acid sequence. In addition, substantially homologous as used herein also refers to substantial correspondence between the amino acid sequence of the V-J or V-D-J junctional sequences of the antigen specific T-cell receptors provided herein and that of any other amino acid sequence.
- Major Histocompatibility Complex (MHC) is a generic designation meant to encompass the histo-compatibility antigen systems described in different species including the human leukocyte antigens (HLA). The term cancer includes but is not limited to, melanoma, epithelial cell derived cancers, lung cancer, colon cancer, ovarian cancer, breast cancer, kidney cancer, prostate cancer, brain cancer, or sarcomas.
- The term melanoma includes, but is not limited to, melanomas, metastatic melanomas, melanomas derived from either melanocytes or melanocyte related nevus cells, melanocarcinomas, melanoepitheliomas, melanosarcomas, melanoma in situ, superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, invasive melanoma or familial atypical mole and melanoma (FAM-M) syndrome. The aforementioned cancers can be treated, assessed or diagnosed by methods described in the present application.
- The lymphocytes of the present invention are pre-selected for TCRs having reactivity with specific antigens. These antigens are preferably strong antigens. The term “strong antigen” as it is referred to herein relates to an antigen capable of inducing proliferation of pre-selected adoptively transferred T cells. Examples of such antigens include but are not limited to alloantigens, viral agents and other foreign agents. Allogeneic agents or “alloantigens” are antigens derived from genetically non-identical members of the same species. Allogeneic tissues, cells, proteins, peptides, nucleic acids and/or other cellular components may be used to select an individual or subpopulation of lymphocytes. Examples of viral agents are well-known in the art, and include, but are not limited to, Epstein Barr virus and the Flu-virus and proteins, peptides, nucleic acids and other cellular components derived therefrom. Examples of other strong antigens include foreign proteins such as serum proteins from other species including bovine.
- “Dual specificity lymphocytes” as that phrase is used herein refers to lymphocytes capable of reacting with both a tumor antigen and a pre-selected strong antigen. The tumor antigen reactivity may be conferred by genetically modifying lymphocytes with a chimeric T cell receptor gene encoding a binding site for the tumor antigen. Tumor antigen reactivity may also be conferred by native TCR itself. Reactivity with the pre-selected strong antigen(s) is preferably conferred by in vitro expansion of the isolated population of lymphocytes by specific T cell activation using one or more pre-selected strong antigens.
- “Chimeric receptor gene” refers to any receptor gene encoding a protein containing an extracellular recognition/binding site and transmembrane and intracellular portions capable of translating the binding of a ligand to the recognition site to specific intracellular activities. Preferably, the chimeric receptor gene encodes sequences for T-cell receptors or parts thereof which recognize tumor associated antigens and/or function to translate extracellular/cytoplasmic signal to intracellular activities in T-cells. One example of such a chimeric receptor gene encodes a single chain variable region from a monoclonal antibody joined to the Fc receptor chain capable of mediating T-cell receptor signal transduction. Another preferred chimeric receptor comprises an antibody variable region joined to the cytoplasmic region of CD28 from a T cell or a similar region which can provide a T cell with co-stimulation signals.
- Additional examples of immune cell trigger molecules are any one of the IL-2 receptor (IL-2R) p55 (α) or p75 (β) or γ chains, especially the p75 and γ subunits which are responsible for signaling T cell and NK proliferation.
- Further candidate receptor molecules for creation of scFv chimeras in accordance with the present invention include the subunit chains of Fc receptors. In the group of NK-stimulatory receptors, the most attractive candidates are the γ- and CD16α-subunits of the low affinity receptor for IgG, FcγRIII. Occupancy or cross-linking of FcγRIII (either by anti-CD16 or through immune complexes) activates NK cells for cytokine production, expression of surface molecules and cytolytic activity [Unkeless, J. C. et al., Annu. Rev. Immunol. 6:251-281 (1988); Ravetch, J. V. and Kinet, J. P. Annu. Rev. Immunol. 9:457-492 (1991)]. In NK cells, macrophages, and B and T cells, the FcγRIII appears as a heterooligomeric complex consisting of a ligand-binding a chain associated with a disulfide-linked γ or zeta chain. The FcγRIIIA signalling gamma chain [Wirthmuller, V. et al., J. Exp. Med. 175:1381-1390 (1992)] serves also as part of the FcεRI complex, where it appears as a homodimer, is very similar to the CD3 zeta chain, and in fact can form heterodimers with it in some cytolytic T lymphocytes (CTL) and NK cells [Orloff, D. G., et al. Nature (London) 347:189-191 (1990); Lanier, L. G., et al. J. Immunol. 146:1571-1576 (1991); Vivier, E., et al. J. Immunol. 147:4263-4270 (1991)]. Most recently prepared chimeras between these polypeptides and the CD4 [Romeo, C. and Seed, B. Cell 64:1037-1046 (1991)], the CD8 [Irving, B. A. and Weiss, A. Cell 64:891-901 (1991)], IL-2 receptor chain [Letourneur, F. and Klausner, R. D. Proc. Natl. Acad. Sci. USA 88:8905-8909 (1991)] or CD16 extracellular domains, proved to be active in signaling T cell stimulation even in the absence of other TCR/CD3 components.
- In one embodiment, the chimeric receptor genes encode amino acid sequences which provide for the V-J or V-D-J junctional regions or parts thereof for the alpha and beta chains of the T-cell receptor which recognize tumor associated antigens. In general, the chimeric T-cell receptors recognize or bind tumor associated antigens presented in the context of MHC Class I. Many different tumor associated antigens are known to the skilled artisan. A tumor antigen can be defined as a molecule that can be used to target therapy against a tumor and includes those antigens only found on tumor cells (i.e. tumor specific), those which are expressed on tumor cells and on limited normal tissues, i.e. differentiation antigens (including cancer-testis antigens) and those which are over-expressed on tumor cells compared to the expression on a wide variety of normal tissues (i.e. over-expressed antigens). Examples of over-expressed antigens include, but are not limited to, Folate binding protein (FBP), Erb-B2, GD-2, HMW-MAA, G250, TAG-72, NY-ESO-1, carcino-embryonic antigen and alpha-fetoprotein. Differentiation antigens include, for example, Tyrosinase, MART-1, MAGE and gp100 of melanoma. Tumor-specific antigens include, for example, mutant Ras, mutant p53, mutant Erb-B2 of a wide variety of tumors including breast and colon. Any of these tumor antigens can serve as the binding agent for the TCR or chimeric receptor. The choice of which antigen to target is within the skill of the ordinary artisan, and is based upon the specific tumor being targeted.
- In one preferred embodiment, the tumor associated antigens recognized by the receptors of this invention are melanoma antigens. By way of example, melanoma specific T-cell receptors may recognize melanoma antigens in the context of HLA-A2.1 or HLA-A1. Examples of melanoma antigens which are recognized by the chimeric receptors include, but are not limited to, MART-1, or peptides thereof or gp-100 or peptides thereof. In a preferred embodiment the chimeric receptor recognizes or binds to the MART-1 peptide, in particular epitopes M9-1 (TTAEEAAGI), M9-2 (AAGIGILTV), M10-3 (EAAGIGILTV), and M10-4 (AAGIGILTVI) (shown in single letter amino acid code) or gp-100 peptide epitopes.
- The chimeric receptor is provided as a recombinant DNA molecule comprising all or part of the T-cell receptor nucleic acid sequence and a vector. The nucleic acid sequences encoding the α and β chains of a T-cell receptor of the present invention may be placed in a single expression vector. Alternatively the α chain and the β chain may each be placed in a separate expression vector. Expression vectors suitable for use in the present invention may comprise at least one expression control element operationally linked to the nucleic acid sequence. The expression control elements are inserted in the vector to control and regulate the expression of the nucleic acid sequence. Examples of expression control elements include, but are not limited to, lac system, operator and promoter regions of phage lambda, yeast promoters and promoters derived from polyoma, adenovirus, retrovirus, cytomegalovirus (CMV), SRα, MMLV, SV40 or housekeeping promoters such as phosphoglycerol kinase (PGK) and β actin. Additional preferred or required operational elements include, but are not limited to, leader sequences, termination codons, polyadenylation signals and any other sequences necessary or preferred for the appropriate transcription and subsequent translation of the nucleic acid sequence in the host system. It will be understood by one skilled in the art that the correct combination of required or preferred expression control elements will depend on the host system chosen. It will further be understood that the expression vector may contain additional elements necessary for the transfer and subsequent replication of the expression vector containing the nucleic acid sequence in the host system. Examples of such elements include, but are not limited to, origins of replication and selectable markers and long terminal repeats (LTR) and internal ribosomal entry site (IRES). The expression vector may also include a leader peptide sequence. It will further be understood by one skilled in the art that such vectors are easily constructed using conventional methods [Ausubel et al., (1987) in “Current Protocols in Molecular Biology”, John Wiley and Sons, New York, N.Y.] or commercially available.
- Alternatively, the chimeric receptor gene may comprise a first gene segment encoding the single chain Fv receptor (scFv) of a specific antibody, i.e., DNA sequences encoding the variable regions of the heavy and light chains (VH and VL, respectively) of the specific antibody, linked by a flexible linker, and a second gene segment which comprises a DNA sequence encoding partially or entirely the transmembrane and cytoplasmic, and optionally the extracellular, domains of a lymphocyte-triggering molecule corresponding to a lymphocyte receptor or part thereof. Thus, the scFvR design may be advantageous over the two-chain version of the receptor. It requires the expression of only one gene instead of the gene pair required for the cTCR, thereby providing simpler construction and transfection.
- The scFv domain may preferably be joined to the immune cell triggering molecule such that the scFv portion will be extracellular when the chimera is expressed. This is accomplished by joining the scFv either to the very end of the transmembrane portion opposite the cytoplasmic domain of the trigger molecule or by using a spacer which is either part of the endogenous extracellular portion of the triggering molecule or from other sources. The chimeric molecules of the present invention have the ability to confer on the immune cells on which they are expressed MHC nonrestricted antibody-type specificity. Thus, a continuous polypeptide of antigen binding and signal transducing properties can be produced and utilized as a targeting receptor on immune cells. In vivo, cells expressing these genetically engineered chimeric receptors will home to their target, will be stimulated by it to attract other effector cells, or, by itself, will mediate specific destruction of the target cells. In a preferred embodiment, the target cells are tumor cells and the scFv domain is derived from an antibody specific to an epitope expressed on the tumor cells. It is expected that such anti-tumor cytolysis can also be independent of exogenous supply of IL-2, thus providing a specific and safer means for adoptive immunotherapy.
- Besides the specific receptor chains specifically mentioned herein, the single chain Fv chimeras can be made by joining the scFv domain with any receptor or co-receptor chain having a similar function to the disclosed molecules, e.g., derived from granulocytes, B lymphocytes, mast cells, macrophages, etc. The distinguishing features of desirable immune cell trigger molecules comprise the ability to be expressed autonomously (i.e., as a single chain), the ability to be fused to an extracellular domain such that the resultant chimera is expressed on the surface of an immune cell into which the corresponding gene was genetically introduced, and the ability to take part in signal transduction programs secondary to encounter with a target ligand.
- The construction options for the production of chimeric T-cell receptor genes and their corresponding proteins can be found in U.S. Pat. No. 5,830,755 and U.S. application Ser. No. 08/547,263, both of which are incorporated herein by reference in toto. In addition, Hwu et al (Can. Res. (1995) 55:3369-3373) and Wang et al (Nat. Med. (1998) 492:168) describe details of introducing a chimeric receptor gene into cells and treating tumors therewith. These references are incorporated herein by reference.
- Specific expansion and specific activation of the T cells containing the chimeric T-cell receptor gene are important parts of the present invention. In one embodiment, the specific expansion step amplifies an individual or a subpopulation of T cells whose endogenous TCR is directed to the strong antigen(s) used to expand the T cells. In this way, T cells which react with the antigen(s) are selected out and amplified from a mixed population of T cells originally obtained from the patient. The expanded lymphocytes are transduced with a chimeric receptor gene. These pre-selected, transduced T cells are introduced into a patient, and the patient is immunized with the strong antigen(s). This in vivo immunization step serves to activate the pre-selected adoptively transferred T cells and to target the lymphocytes to the cancer antigen through the chimeric receptor.
- In a preferred embodiment of the invention, patients undergo leukapheresis to obtain peripheral blood lymphocytes (PBL). The lymphocytes are separated from other cells. Various methods of separation are known to the artisan and can be utilized. One preferred separation technique employs centrifugation on a Ficoll cushion. The preferred host cells transformed with all or part of the chimeric receptor nucleic acid sequences may include JURKAT-cells, T-lymphocytes, peripheral blood cells such as peripheral blood lymphocytes (PBL) and peripheral blood mononuclear cells (PBMC), dendritic cells, monocytes, stem cells, natural killer (NK) cells or macrophages.
- Candidate immune cells to be endowed with antibody specificity using this approach are: NK cells, lymphokine-activated killer cells (LAK), cytotoxic T cells, helper T cells, and the various subtypes of the above. These cells can execute their authentic natural function and can serve, in addition, as carriers of foreign genes designated for gene therapy, and the chimeric receptor shall serve in this case to direct the cells to their target. This approach can be applied also to anti-idiotypic vaccination by using helper T cells expressing chimeric receptors made of Fv of antiidiotypic antibodies.
- The cells are activated with one or more preselected antigens. Any strong antigen, i.e. one that is capable of inducing proliferation of the adoptively transferred lymphocytes, may be utilized for the activation/selection step. The lymphocytes are preferably exposed to the strong antigen for greater than one hour in the case of proteins and virus or for at least 24 hours, preferably, continuously, for allogeneic cells as strong antigens. The strong antigen is provided up to a concentration of 1 millimolar when proteins, peptides or cellular components are used or at a ratio of one dual specific T-cell to 1-1000 infectious viral particles or between 1 and 100 allogeneic cells per each dual-specific T-cell. A combination of several stimuli may optionally be included in the activation/selection mixture. One preferred embodiment utilizes a donor's PBLs as an allogeneic agent. When donor PBLs are used, selection is carried out by co-culture of irradiated donor PBMC with patient PBMC at a ratio preferably with the range of 2:1 to 5:1.
- These cells are transduced with a chimeric receptor gene. “Transduction” or introduction of foreign DNA into the immune cells may be carried out by any manner known in the art, such as, for example, microinjection, electroporation, transduction, retroviral transduction or transfection using DEAE-dextran, lipofection, calcium phosphate, particle bombardment mediated gene transfer or direct injection of nucleic acid sequences encoding the chimeric receptors or other procedures known to one skilled in the art [Sambrook et al. (1989) in “Molecular Cloning. A Laboratory Manual”, Cold Spring Harbor Press, Plainview, N.Y.]. One preferred method of transduction follows the method described in Hwu, et al., (1993) J. Immunol. 150:4104-4115. One preferred method of transduction resuspends the lymphocyte preparation in a retroviral supernatant at a concentration range of 1×102 to 1×101° per ml, more preferably at a range of 1×104 to 1×108, most preferably at a concentration of 1×106. Transduction may preferably be followed by a selection step, such as for example using an antibiotic selection marker on the chimeric receptor gene construct, such as the neomycin resistance gene.
- The preselected transduced lymphocytes may be cultured for several days. Between days 14-21, it may be desirable to screen the cells for specific cytokine release against ovarian tumor antigens and/or assay for phenotype integrity. At this time, it may also be desirable to restimulate the lymphocyte population with the strong antigen. Restimulation using a strong antigen is preferably carried out at a similar concentration as used for the initial stimulation for a similar time period. If donor cells are used as the allogeneic agent, restimulation is preferably carried out at a ratio of 0.5:1 to 4:1, more preferably at a ratio of 1:1 to 2:1 (donor:patient). These cells can be directly reintroduced into the patient or can be frozen for future use, i.e. for subsequent administrations to this patient.
- Upon expansion of lymphocytes in IL-2 containing media, patients receive preselected transduced lymphocytes intravenously. Optionally, the patient may also receive IL-2, preferably after the lymphocyte infusion. It is preferable that the IL-2 be provided at a dosage range of 1200 IU/kg to 1,200,000 IU/kg, more preferably at 120,000 IU/kg every 12 hours. After the first administration, patients may again receive preselected, transduced lymphocytes intravenously with or without similar doses of IL-2. Dual specificity lymphocytes are administered at a dosage range of 1×106 to 1×1015, more preferably 1×108 to 1×1011, most preferably 3×109 to 5×101° cells. Further details on dosage and frequency of cells are provided in U.S. Pat. No. 5,399,346, which is incorporated herein by reference, in toto.
- The present invention provides a method of inhibiting or preventing the growth of tumor cells by exposing tumor cells to the dual specificity lymphocytes provided herein. The dual specificity lymphocytes may be used for either prophylactic or therapeutic purposes. When provided prophylactically, the dual specificity lymphocytes is provided in advance of any evidence or symptom in the mammal due to cancer, in particular, melanoma. The prophylactic use of the dual specificity lymphocytes serves to prevent or attenuate cancer, in particular melanoma, in a mammal. When provided therapeutically, dual specificity lymphocytes are provided after the onset of the disease in the mammal. The therapeutic administration of the dual specificity lymphocytes serves to attenuate the disease.
- Cell-based immunotherapy currently utilizes the adoptive transfer to patients of tumor specific TIL which are generically expanded ex vivo [Rosenberg S. A. 1992. J. Clin. Oncol., 10:80; Rosenberg S. A., et al. N. Engl. J. Med., 319:1676; Hwu P., et al. 1993. J. Exp. Med., 178:361]. T-cell specificity may be redirected by combination of the in vitro transfer of the nucleic acid sequences encoding the tumor associated antigen specific T-cell receptors and selective expansion of the lymphocytes with one or more strong antigens. By way of example, a heterogenous population of T-cells, such as TIL, may be made more effective by conferring anti-tumor reactivity to non-specific T-cell populations within the TIL, and selective expansion of T lymphocytes to amplify T lymphocytes reactive with one or more pre-selected strong antigens.
- Cells that can be modified to produce dual specificity lymphocytes include, but is not limited to, lymphocytes, cytotoxic T-lymphocytes, hematopoietic stem cells, monocytes, stem cells, peripheral blood and natural killer cells. In a preferred embodiment, T-cells can be genetically modified to express the tumor antigen specific T-cell receptors. Constructs containing all or parts of the nucleic acid sequences encoding the chimeric T-cell receptors may be introduced in T-lymphocytes by conventional methodology. By way of example such methods include, but are not limited to, calcium phosphate transfection, electroporations, lipofections, transduction by retroviruses, injection of DNA, particle bombardment and mediated gene transfer use of a retroviral vector, viral vectors, transduction by viral co-culturing with a producer cell line. Preferably, the construct or constructs carrying the nucleic acid sequences encoding the chimeric T-cell receptors are introduced into the T-cells by transduction with viral supernatant or co-cultivation with a retroviral producer cell line. Examples of vectors that may be used include, but are not limited to, defective retroviral vectors, adenoviral vectors, vaccinia viral vectors, fowl pox viral vectors, or other viral vectors [Mulligan, R. C., (1993) Science 260:926-932]. Eukaryotic expression vectors G1EN [Treisman, J., et al., Blood, 85:139; Morgan et al. (1992) Nucleic Acids Res. 20:1293-1299], LXSN [Miller, A. D., et al. Methods Enzymol., 217:581-599 (1993); Miller, A. D., et al. BioTechniques, 7:980-988 (1989); Miller, A. D., et al., Mol. Cell Biol., 6:2895-2902 (1986); Miller, A. D. Curr. Top. Microbiol. Immunol., 158:1-24 (1992)], and SAM-EN [Treisman, J., et al., Blood, 85:139] may also be used. Individual constructs carrying the genes coding for the alpha and beta chains that comprise the receptor may be introduced into the T-lymphocytes or alternatively, an individual construct carrying the nucleic acid sequences encoding for both the α and β chains of the T-cell receptor may be in a single construct. Preferably, a retroviral vector, for example a vector with the murine moloney leukemia viral LTR promoting transcription of the T-cells receptor genes is used. In a preferred embodiment non-replicating retroviral vectors are used. Alternatively, the genes can be expressed using an internal housekeeping promoter, such as that from the phosphoglycerol kinase (PGK) gene.
- The α and β chains of the T-cell receptor may either be expressed on separate retroviral vectors, or on the same retroviral vector, separated by an internal ribosomal entry site (IRES) [Treisman, J., et al., Blood, 85:139; Morgan, R. A., et al., Nucleic Acids. Res., 20:1293-1299 (1992)]. Using an IRES-containing vector, allows both T-cell receptor genes to be translated from a single RNA message. Examples of where T-lymphocytes can be isolated, include but are not limited to, peripheral blood cell lymphocytes (PBL), lymph nodes, or tumor infiltrating lymphocytes (TIL), or blood. Such lymphocytes can be isolated from the individual to be treated or from a donor by methods known in the art and cultured in vitro [Kawakami, Y. et al. (1989) J. Immunol. 142: 2453-3461]. Alternatively, a single chain Fv receptor gene may be constructed and used as the chimeric receptor gene.
- The T-cells may be incubated with a retroviral producer cell line carrying retroviral expression vectors or with viral supernatant. Viability of the lymphocytes may be assessed by conventional methods, such as trypan blue dye exclusion assay. The genetically modified lymphocytes expressing the desired melanoma specific T-cell receptor may then be administered to a mammal, preferably a human, in need of such treatment in a therapeutically effective amount. The dosing regimes or ranges of lymphocytes used in the conventional tumor infiltrating lymphocyte (TIL) therapy [Rosenberg, et al. (1994) J. Natl. Canc. Inst., Vol. 86:1159] may be used as general guidelines for the doses or number of T-lymphocytes to be administered to mammal in need of such treatment. By way of example, a range of about 1×1010 to about 1×1011 T-cells for each cycle of therapy may be administered in the methods provided herein. Examples of how these antigen specific T-cells can be administered to the mammal include but are not limited to, intravenously, intraperitoneally or intralesionally. Parameters that may be assessed to determine the efficacy of these transduced T-lymphocytes include, but are not limited to, production of immune cells in the mammal being treated or tumor regression. Conventional methods are used to assess these parameters. Such treatment can be given in conjunction with cytokines or gene modified cells [Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 75-90; Rosenberg, S. A. et al. (1992) Human Gene Therapy, 3: 57-73] chemotherapy or active immunization therapies. One of skill in the art will appreciate that the exact treatment schedule and dosages, or amount of T-lymphocytes to be administered may need to be optimized for a given individual.
- This invention also relates to pharmacological compositions comprising the dual specificity lymphocytes. The formulations of the present invention, both for veterinary and for human use, comprise each component individually or as a composition as described above, together with one or more pharmaceutically acceptable carriers and, optionally, other therapeutic ingredients. The carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations may conveniently be presented in unit dosage form and may be prepared by any method known in the pharmaceutical art.
- Preparation of the Pharmaceutical Compositions Include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation.
- Formulations suitable for intravenous intramuscular, subcutaneous, or intraperitoneal administration conveniently comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient. Such formulations may be conveniently prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered pH compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. These may be present in unit or multi-dose containers, for example, sealed ampoules or vials.
- The formulations of the present invention may incorporate a stabilizer. Illustrative stabilizers are polyethylene glycol, proteins, saccharide, amino acids, inorganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part by weight of each component or the composition. If two or more stabilizers are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and pH. The specific osmotic pressure of such aqueous solutions is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8-1.2. The pH of the aqueous solution is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8. In formulating each component separately or as a composition of the present invention, anti-adsorption agent may be used.
- Additional pharmaceutical methods may be employed to control the duration of action. Controlled release preparations may be achieved through the use of polymer to complex or absorb the cells or their derivatives. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the concentration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled-release preparations is to incorporate the 9-cis-retinoic acid or derivatives thereof alone or in combination with antineoplastic agents thereof into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions.
- When oral preparations are desired, the component may be combined with typical carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others.
- The administration of the compositions or of each individual component of the present invention may be for either a prophylactic or therapeutic purpose. The methods and compositions used herein may be used alone in prophylactic or therapeutic uses or in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of cancer. Alternatively the methods and compositions described herein may be used as adjunct therapy. Veterinary uses are also intended to be encompassed by this invention.
- All references cited herein, including journal articles or abstracts, published or corresponding U.S. or foreign patent applications, issued U.S. or foreign patents, or any other references, are entirely incorporated by reference herein, including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.
- Reference to known method steps, conventional methods steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.
- The invention will now be illustrated by the following non-limiting examples.
- Previously, chimeric receptors against ovarian cancer (MOv-γ) were found to be functional in primary T cells in vitro and in vivo [Hwu, P., et al. J. Exp. Med., 178:361-366, 1993; Hwu, P., et al., Cancer Res., 55:3369-3373, 1995]. The effects of treating eight patients with advanced ovarian cancer with T cells transduced with chimeric receptor genes derived from a monoclonal antibody against ovarian cancer, MOv-18 alone, and without any specificity were observed. Tumor-infiltrating lymphocytes (TIL) or anti-CD3 stimulated peripheral blood lymphocytes (PBL) retrovirally transduced with the MOv-18 chimeric receptor gene (MOv-7) were generated in large numbers of MOv-PBL which remained highly reactive against ovarian cancer cells in vitro prior to infusion. Patients were treated with up to 5×101° transduced PBL for CD3 in combination with systemic IL-2 (120,000 CU/kg). The results of this clinical trial demonstrated that cells were directed to lung, liver, and spleen, but did not specifically localize at tumor sites. Despite specific in vitro reactivity of MOv-PBL against ovarian cancer cells, none of the patients responded to the lymphocyte infusion. The number of circulating transduced cells following MOv-PBL infusion was determined. Between 4-6 days following MOv-PBL infusion, between 0.01 and 1% circulating transduced cells were detected; however, between 12-31 days, the majority of transduced cells were undetectable.
FIG. 2 shows the percentage of circulating transduced cells during the course of the treatment after MOv-PBL infusion. - In order to address the question as to why patients transduced with chimeric receptor genes did not respond to treatment although 10% of transduced cells were found circulating in one patient's PBMC analyzed after 5 days post MOv-PBL infusion, the functionality of MOv-PBL after cell transfer was determined. Fresh uncultured PBMC from the
day 5 post MOv-PBL infusion time point were co-cultured with ovarian cancer cells or melanoma cells (888 mel or 1300 mel). Supernatants were assayed for IFN-γ by enzyme-linked immunosorbent assay (ELISA) and lysates were analyzed for IFN-γ mRNA using Taqman. No significant IFN-γ release was seen using thefresh day 5 PBMC. To reisolate the adoptively transferred MOv-PBL, the PBMC fromday 5 were cultured in G418 (for neomycin resistant selection), anti-CD3, and IL-2. After 17 days, the culture was highly enriched for reisolated MOv-PBL (69% positive for gene) that were capable of specifically producing large amounts of cytokine in response to ovarian tumor cells. As measured by IFN-γ release (pg/ml), Table 1 shows that MOv-PBL retained their ability to recognize tumor after adoptive transfer. The NV PBL group did not result in IGROV or melanoma reactivity. The NV PBL and G418 group also did not result in significant IGROV, 888 mel, or 1300 mel reactivity. Both cultured MOv-PBL and the reisolated PBL were significantly IGROV-reactive. These results indicate that MOv-PBL retained their ability to recognize tumor after adoptive transfer, although culturing was necessary to observe anti-tumor reactivity. -
TABLE 1 IFN-γ Release (pg/ml) GROUP IGROV 888 mel 1300 mel NV PBL 0 0 0 NV PBL + G418 0 49 0 MOv-γ transduced 3582 3 14 PBL Reisolated PBL 2912 0 192 - In order to determine the effects of allogeneic immunization of adoptively transferred T cells, anti-allogeneic mouse (C57BL/6) T cells were raised in a mixed lymphocyte reaction (MLR) for 7 days and restimulated for 6 additional days. Thy 1.1+ alloreactive (H2-b anti-H2-d) T cells were generated and expanded and 1×107 cells were adoptively transferred into congenic C57BL/6 mice (Thy 1.2) by intravenous injection. The C57BL/6 mice were immunized with allogeneic antigen presenting cells from BALB/c mice on
days day 11 and Thy 1.1 cells were quantified following staining and fluorescence-activated cell sorter (FACS) analysis. The percent of Thy 1.1 cells in tissue was measured by comparing those immunized with allogeneic splenocytes and allogeneic DC. Adoptively transferred, cultured alloreactive T cells were found to expand in vivo following immunization with allogeneic antigen presenting cells and increased the survival of in vitro-cultured, adoptively transferred allo-reactive T cells upon immunization with allogeneic cells (FIGS. 3A and 3B ). - C57BL/6 mice T cells (2×107) were raised in a mixed leukocyte reaction (MLR) in 24 well plates and 10 CU/ml IL-2 with restimulation on
day 7. G418 (0.5 mg/ml) was added for 6 days untilday 13 and assayed for MOv-'y expression and IFN-γ secretion in response to various target cells. The results of Table 2 andFIG. 4 show that dual specificity T cells expressing chimeric MOv-γ with significant anti-allogeneic and anti-FBP activity as measured by IFN-γ (pg/ml) was generated. -
TABLE 2 Non-transduced T Media cells MOv-γ T cells Media 0 0 0 CT26 (allogeneic 0 65,200 138,700 H-2d) 24JK (H-2b) 0 0 0 24JK- FBP 0 0 5200 888 mel 0 0 0 IGROV (ovarian 0 0 37,500 FBP+) - C57BL/6 mice received 1×107 dual specificity allogeneic/MOv-γ T cells followed by subcutaneous immunization with 5×107 allogeneic splenocytes from
donor mice 2 days later. Seven days after immunization, mice were challenged with 2×105 24JK-FBP ovarian cancer tumor cells subcutaneously. The 24JK is a clone from the 3-methylcholanthrene-induced, poorlyimmunogenic MCA 102 murine sarcoma, where 24JK-FBP is 24JK transduced with the folate binding protein (FBP) gene, which is expressed highly on ovarian adenocarcinomas and MOv-γ is a mAb that binds FBP. Five mice per condition were then monitored for 20 days. FIG. 5 shows that in vivo immunization with allogeneic splenocytes from donor mice, in combination with administration of dual specificity T cells protected mice much more significantly than T cells alone. Specifically, the combined conditions result in 100% tumor-free mice while mice infused with dual specificity T cells alone resulted in 25% tumor-free mice. - In order to determine whether the combination of adoptively transferred dual specificity T cells and immunization with allogeneic cells can inhibit established subcutaneous tumors, 3 RAG-1 immunodeficient knock out mice per condition were injected on
day 0 with 2×105 tumor cells, specifically, 24JK and 24JK-FBP tumor cells. Onday 3, mice received either 1×107 dual specificity T cells, 1×107 non-transduced (NV) T cells, or no treatment. Subcutaneous immunization with 5×107 allogeneic splenocytes was performed ondays day 15, one mouse per group having a middle sized tumor was sacrificed in order to determine the effect of immunization on transferred T cell numbers. Dual specificity T cells inhibited the tumor and this effect was augmented by immunization.FIG. 6 shows that mice injected with 24JK-FBP tumor cells followed by transduced dual specificity T cells and immunization or boost, resulted in the smallest tumor size throughout the time course of 29 days. - Since murine studies indicated that dual specificity T cells can be generated and functional, used for prevention, and treatment of tumors, dual specificity human T cells were generated. On
day patients donor 269 PBMC (5×105 T cells and 2×105 irradiated stimulators/well). Ondays day 27 cells were restimulated withdonor 269 PBMC as above. On day 35, the bulk population was assayed and cloned at 1 cell/well using standard surgery branch (SB) method with OKT3 stimulation and PBMC from another donor. Results indicated that human anti-allogeneic T cells raised fromPBMC FIG. 7 ). On days 49-52, the clones were characterized. The anti-allogeneic reactivity ofPBMC 399 clones as measured by GM-CSF release (pg/ml) indicated that 62.5% of the clones were allo-reactive, 23.5% of the top 17 allo-reactive clones were demonstrated to be IGROV-reactive, and 12% were both allo-reactive and IGROV-reactive. The anti-allogeneic reactivity ofPBMC 363 clones as measured by GM-CSF release indicated that 58% of the clones were alto-reactive, 57% of the top 7 allo-reactive clones were IGROV-reactive, and 36% were both allogeneic- and IGROV-reactive. Phenotypic characterization of the bulk population is described by FACS analysis (FIGS. 8A-8F ), whereFIGS. 8A-8C represent the phenotype for the bulk population ofpatient 399 anti-269 andFIGS. 8D-8F represent the phenotype for the bulk population ofpatient 363 anti-269.FIGS. 8A and 8D show the control results using non-specific IgG2a;FIGS. 8B and 8E describe the CD4 and/or CD8 phenotype of the population of cells; andFIGS. 8C and 8F show the shift of the MOv antibody-stained cells which represents the presence of the ovarian cancer (MOv)-specific receptor on T cells. - In order to determine whether or not individual T cells were both allogeneic- and MOv-γ-reactive, PBMC from patient 410 were used to generate and characterize dual specificity T cells. On
day days FIG. 9 show that non-transduced T cells are allogeneic-reactive, whereas, bulk MOV-γ transduced 410 T cells are both allogeneic- and IGROV-reactive as measured by GM-CSF release (pg/ml).FIGS. 10A-10B and Table 3 describe the phenotypic characteristic of the bulk population of patient 410 anti-556 donor cells. The majority of cells are CD4 helper T cells and were found to be reactive against IGROV. Therefore, dual specificity human T cells can be grown to recognize both allogeneic targets as well as tumor. Table 4 shows GM-CSF secretion from ten of the most reactive transduced dual specificity PBMC 410 clones. These results confirm that each clone is both alloreactive as demonstrated by the high GM-CSF release in response to PBMC 556 donor and specific for ovarian cancer as demonstrated by the high GM-CSF secretion in response to IGROV.FIGS. 11A-11J show the phenotype characterizations of representative selectedclones -
TABLE 3 Quad Events % Gated % Total CD4+/CD8− 6237 82.27 43.42 CD4+/CD8+ 233 3.07 1.62 CD4−/CD8− 116 1.53 0.81 CD4−/CD8+ 995 13.12 6.93 -
TABLE 4 CLONE 1 2 3 4 5 6 7 8 9 10 PBMC410 1010 650 1790 640 1580 2380 2330 70 250 0 PBMC556 2300 2410 >5000 3200 >5000 4870 >5000 3050 1330 1020 888 105 0 20 0 750 130 100 0 0 10 mel IGROV 2820 2690 2770 2200 3440 4850 2380 2290 5270 2400 - In order to maximize proliferation and reactivity against both allogeneic and tumor targets which can be utilized for patient treatment, the type of stimulator cells, the stimulator:responder ratio in MLR, IL-2 concentration, and conditions for restimulation must be optimized. Therefore, 2×106 fresh responder PBMC from a normal donor were incubated in wells of a 24 well plate with a stimulator comprising one of irradiated allogeneic PBMC, B cells, or DC at the following stimulator to responder ratios: 5:1, 1.5:1, 1:2, 1:6, 1:20, and 1:60 in AIM-V/5% human serum; 100 CU IL-2/ml). After 3 days incubation, the cells were transduced with MOv-γ/TCR by replacing of the media with retroviral supernatant followed by centrifugation at 2700 rpm for 1 hour. Transduction was repeated the following day, and cells were then selected in 0.5 mg/ml G418.
FIGS. 12A-12D show growth curves following stimulation with various allogeneic cell types and at various stimulator:responder ratios.FIG. 12D is the control responder without stimulators. Table 5 describes the phenotype of T cell cultures generated from a variety of APC and stimulator to responder ratios onday 17. - Tables 6-9 show the results of functional assays of cells on
day 17 after stimulation for the various APC and stimulator: responder ratios, where the different ratios were performed in duplicates. Allogeneic PBMC were determined to be good stimulators for MLR, and result in high levels of expansion when using stimulator:responder ratios ranging from 1.5:1 to 5:1. Functional assays demonstrated that transduced cells generated from PBMC stimulators were capable of recognizing allogeneic and tumor targets. -
TABLE 5 Phenotype CD4+/ APC Stim:Resp CD3+ CD4+ CD8+ CD4+/CD8+ CD8− PBMC 1:60 93 4 51 2 43 1:20 94 4 49 2 45 1:6 1:2 88 9 43 4 45 1.5:11 91 15 41 5 40 5:1 95 19 42 7 32 DC 1:60 96 9 54 5 33 1:20 99 25 44 10 21 1:6 100 64 11 20 5 1:2 ND ND ND ND ND 1.5:1 ND ND ND ND ND 5:1 ND ND ND ND ND B-cells 1:60 90 10 41 4 45 1:20 86 18 34 6 42 1:6 88 25 28 8 40 1:2 96 54 16 12 18 1.5:1 98 67 12 15 7 5:1 99 76 10 11 3 OKT3 — 99 56 27 16 2 No — 93 5 52 3 40 OKT3 (ND = Not done) (CD4/CD8 double negative cells were CD3+, CD19−, CD14−, CD11c−) -
TABLE 6 PBMC (IFN gamma pg/ml) Stim:resp 1:60 1:20 1:6 1:2 1.5:1 5:1 media 59 48 37 31 33 38 27 24 44 34 50 49 alone IGROV-1 2785 2200 3122 2973 3320 2815 2319 2349 3251 3755 4733 4279 888 185 614 165 172 65 66 38 42 65 69 100 91 stim. 107 97 174 261 443 631 548 612 1553 1693 1802 1244 PBMC responder 245 156 212 176 131 136 313 118 141 148 269 172 PBMC coated 7018 7155 5916 6172 4950 6083 3627 3765 5078 5019 >11060 7391 OKT3 -
TABLE 7 DC (IFN gamma pg/ml) Stim:resp 1:60 1:20 1:6 media alone 28 34 27 27 28 60 IGROV-1 2636 3102 3785 4131 1583 889 888 79 74 471 422 51 62 stim. PBMC 995 1054 1683 1463 1553 1921 responder 350 121 76 85 104 57 PBMC coated OKT3 5965 7019 9385 9727 6211 5108 -
TABLE 8 B Cells (IFN gamma pg/ml) Stim:resp 1:60 1:20 1:6 1:2 1.5:1 5:1 media 30 35 30 41 81 62 39 28 10 10 7 2 alone IGROV-1 1374 1543 2894 3270 4634 3548 3686 3181 1583 1463 350 341 888 124 122 79 63 100 95 47 45 11 11 2 3 stim. 680 1090 1433 1314 1081 895 761 518 308 228 96 123 PBMC responder 139 114 399 161 349 133 83 79 50 44 31 33 PBMC coated 7096 4999 5640 4871 6240 7303 6014 5916 5384 5728 886 994 OKT3 -
TABLE 9 Stimulators (IFN gamma) +OKT3 No OKT3 media alone 2 0 23 23 IGROV-1 1832 2259 2646 2587 888 16 18 50 84 stim. PBMC 16 17 43 72 responder 90 50 189 131 PBMC coated OKT3 3656 3815 6585 5561 - Following the first stimulation, 4×105 of the T cells from each group were added to the appropriate number and type of stimulator cells (from the same allogeneic donor) in a 24 well plate with 50 CU IL-2/ml and 5% AIM-V human serum. IL-2 (50 CU/ml) was added every 2 days.
FIGS. 13A-13D show the number of transduced cells upon further stimulation. - Human alloreactive T cells from cryopreserved cells were generated using PBMC at a ratio of 1:1 (2×106 stimulator to 2×106 responder/well), in the presence of various IL-2 concentrations. T cells were transduced with MOv-γ and selected in 0.5 mg/ml G418 for 5 days. Proliferation and reactivity against allogeneic and tumor targets were determined.
FIG. 14 shows T cell growth in MLR with various IL-2 concentrations in CU/ml. Results indicate that as the concentration of IL-2 increases, the number of T cells generated also increases. The phenotypic characteristics of T cell cultures generated from a variety of IL-2 concentrations is depicted in Table 10. At all concentrations of IL-2, T cells are predominantly CD3-1- and then CD4+. In Table 11, the function of MOv-γ transduced alloreactive T cells grown in a variety of IL-2 concentrations as measured by IFN-γ release (pg/ml) demonstrates that 50 CU IL-2/ml provides good expansion, as well as a high level of reactivity against both allogeneic and tumor targets. -
TABLE 10 [IL-2] Phenotype (CU/ml) CD3+ CD4+ CD8+ CD4+/CD8+ CD4+/CD8− 12.5 80 50 23 4 22 25 83 58 22 7 14 50 71 49 22 2 27 100 70 38 28 6 28 -
TABLE 11 Stimulator (IFN gamma pg/ml) media Responder Stimulator alone 888 mel IGROV-1 PBMC PBMC media alone 0 0 0 0 0 0 0 0 0 0 12.5 CU/ml IL-2 4 0 353 318 879 725 278 263 3900 3850 25 CU/ml IL-2 4 4 118 138 2280 2140 239 210 2420 3450 50 CU/ml IL-2 2 12 68 77 2460 2210 235 248 4880 4830 100 CU/ml IL-2 8 8 746 688 2900 2900 231 247 1850 2830 - Serum-free AIM-V medium is supplemented with penicillin G (50 units/ml), and L-glutamine (292-584 mg/ml, 2 mM), as well as IL-2 (100 CU/ml). If necessary, AIM-V medium can also be supplemented with 1-10% human serum (type AB heat inactivated at 56° C. for 30 minutes).
- PBL is isolated by leukapheresis. Lymphocytes are separated by centrifugation 1000 g (2700 rpm) on a Ficoll cushion. PBL is subjected to multiple exposures of retroviral supernatant, for up to 3 days. The PBL is then selected for 5 days in 0.5 mg/ml of the neomycin analog G418 (Geneticin; Gibco; Grand Island, N.Y.). Following G418 selection, PBL is expanded in AIM V media with 100 CU/ml IL-2. If necessary, AIM V is supplemented with 1-10% human AB serum. The exact days stated below is an approximation of what is expected for PBL transduction.
- On
Day 0, isolate PBMC from the leukapheresis preparation from patient and donor by Ficoll-Hypaque gradient centrifugation. Wash in Ca2+-, Mg2+-, Phenol red free Hanks' balanced salt solution (HBSS; BioWhittaker), then resuspend in AIM V medium supplemented with 50 CU/ml of IL-2. Irradiate donor PBMC with 5000 rads. Co-culture irradiated donor PBMC with patient PBMC at a ratio of 2:1 to 5:1. - On
Day 3, harvest PBMC and resuspend in retroviral supernatant supplemented with 50 CU/ml of IL-2 and 8 μg/ml polybrene. Replate PBMC at a concentration of 1×106 per ml; 2 ml per well in 24 well plates. Centrifuge plates at 1000 g (2700 rpm in Sorvall tabletop centrifuge) for 1 hour. - On
Day 4, remove 1 ml of media per well and replace with 1 ml of freshly thawed retroviral supernatant supplemented with 50 CU/ml of IL-2 and 8 μg/ml polybrene. Centrifuge plates at 1000 g (2700 rpm in Sorvall tabletop centrifuge) for 1 hour. - On
Day 5, remove two-thirds of media per well and replace with AIM V medium supplemented with 50 CU/ml of IL-2. - On
Day 6, harvest the PBL, and resuspend at 1×106 per ml in AIM V medium supplemented with 50 CU/ml of IL-2 and 0.5 mg/ml G418. Replate cells in appropriate size Fenwal bag (Baxter) or T-175 tissue culture flask.Aliquot 5×106 cells from non-transduced (NV) and transduced PBL groups for PCR analysis. - Every 2-3 days, count cells and dilute to 1×106 cells per ml in AIM V medium supplemented with 50 CU/ml of IL-2 and 0.5 mg/ml G418.
- On
day 11, harvest the PBL, and resuspend at 1.5×106 per ml in AIM V medium supplemented with 50 CU/ml of IL-2. Replate cells in appropriate size Fenwal bag or T-175 tissue culture flask. - Between Days 14-21, the PSL are screened for specific cytokine release against the ovarian tumor cell line IGROV-1, and phenotype by FACS analysis.
Aliquot 5×106 transduced, selected PBL for PCR analysis. Send samples for S+L-assay for retrovirus. - On approximately
day 21, the patient PBMC are restimulated with irradiated donor PBMC at a ratio of 1:1 to 2:1 (donor:patient). - The density of PBL is maintained between 1×106 and 2.5×106 PBL/ml. Once PBL have begun to grow, the cultures are assessed for growth every 3-4 days to insure that they do not increase beyond 2.5×106/ml.
- Once the total PBL count reaches about 5×108, PBL are removed from the tissue culture plates or flasks and cultured further in Fenwal PL732 cell culture bags. These bags have a 1-liter capacity, but normally 500 mls medium are the maximum used in each bag. PL732 bags are gas permeable, but impermeable to fluids. Thus, oxygen and CO2 are freely exchanged while tissue culture medium and cells are maintained inside. Using an inverted syringe (plunger removed), suspended by a clamp on a ring stand, connect the needle-adapter end of the syringe to the female-luer port of the 1 liter PL732 bag. Pour the cells from the 250 ml conical centrifuge tube into the bag through the syringe, and to obtain a cell concentration of 1×106 PBL/ml add the appropriate volume of fresh AIM-V (serum-free medium) containing the following added supplements (final concentrations): 50 units/ml penicillin G sodium (BioWhittaker), 146 g/ml L-glutamine (Media Tech), 1.25 mg/ml Fungizone, and IL-2 (50 CU/ml).
- As the PBL continue to grow, they are transferred to a 3 liter capacity PL732 bag (1500 ml/bag, 1.5×109 PBL/bag) via the male- and female-luer sterile tubing ports of both the 1 liter and 3 liter bags. The appropriate volume of AIM V medium is then added to maintain the PBL at 1×106/ml. Medium is added to the 3 liter bag using the same sterile tubing attached to an inverted syringe, as described above. PL732 bags are advantageous in that access to the medium containing cells is limited to injection sites and sterile tubing ports, both of which can be maintained aseptically.
- After the PBL are transferred to PL732 bags, PBL cell counts are done every 3-4 days. When the PBL density reaches 2.0×106/ml or greater, the PL732 bags containing medium and PBL are “split” 1:2 or 1:3 to reduce the PBL concentration to a level of 1×106/ml or a bit above. For example, a 1:2 split of cells at 2.0×106/ml involves transferring 500 mls of medium (containing PBL) to a new 3 liter PL732 bag and adding 500 mls of AIM-V containing IL-2 to bring the total volume up to 1000 ml. The AIM-V being added to the 3 liter PL732 bag is transferred from a 10 liter STAK PACK of AIM-V medium (GIBCO; Life Technologies, Grand Island, N.Y.) using a sterile Solution transfer set, Life-adapter set, 8″ Interconnecting jumper tube, and a Fluid fill/weigh unit.
- When PBL have been expanded beyond 3 bags (about 1500 mls each), at least 4×109 cells (generally)1×101° may be removed for bulk freezing in a bag, keeping at least 4×109 PBL in culture in order to generate cells for treating the patient. For a rapidly growing culture, the PBL might be removed a week before treatment. However, for slower growing PBL might not be removed for freezing until the day of harvest. PBL are commonly used for treatment after 14-45 days in culture.
- In general, PBL doubling time is 1.5 to 3 days. Thus, PBL cultures are generally split to new bags containing fresh medium every 3-5 days. Fungizone is left out of the last passage of cells in bags to minimize adverse effects on the patients. Of note, a sample is collected from the last passage of PBL for microbiology tests; this should be done 2-5 days prior to the beginning of PBL therapy. The test takes 2 days. The bags are then harvested for treatment using an automated process of cell harvesting as described by Muul, et al. J. Immunol. Methods 101:171, 1987).
- Following the last split of cells prior to use for treatment, tests are done for bacterial and fungal contamination from samples representing 10% of the bags. If treatment occurs earlier than expected, such that Fungizone is present in the PBL growth medium, PBL harvested for treatment should be washed with 9 liters of isotonic saline, rather than the usual 3 liters. Cells can be infused with up to 75,000 CU IL-2 per infusion bag.
- PBL are infused in a volume of 200-300 ml of saline supplemented with 50 ml of 25% human albumin (Alpha Therapeutic Co.). Cells are infused over 30-60 minutes through a central venous catheter. Patients receiving dual specificity cells are immunized with
donor PBMC - Cryopreserved, transduced PBL can be thawed for subsequent cycles or courses of therapy. If necessary, repeat transduction may be performed on either fresh PBL or cryopreserved, non-transduced PBL.
- IL-2 is administered at a dose of 120,000 CU/kg as an intravenous bolus over a 15 minute period every twelve hours beginning on the day of PBL administration and continuing for up to eight doses. Doses may be skipped depending on patient tolerance. Also, if patients reach Grade III or IV toxicity (not easily reversed) due to IL-2 except for the reversible Grade III toxicities common to IL-2 such as diarrhea, nausea, vomiting, hypotension, skin changes, anorexia, mucositis, dysphagia, or constitutional symptoms and laboratory changes as detailed in Table 12, doses are not administered. If this toxicity is easily reversed by supportive measures then additional doses are given. No more than 12 doses of IL-2 is ever administered.
-
TABLE 12 Toxicity of Treatment with IL-2 Total Number of patients 652 Number of courses 1039 Chills 399 Pruritus 180 Necrosis 5 Anaphylaxis 1 Mucositis (requiring liquid diet) 30 Alimentation not possible 4 Nausea and vomiting 666 Diarrhea 596 Hyperbilirubinemia (maximum/mg %) 2.1.-6.0 547 6.1-10.0 179 10.1+ 83 Oliguria <80 ml/8 hours 347 <240 ml/24 hours 42 Weight gain (% body weight) 0.0-5.0 377 5.1-10.0 436 10.1-15.0 175 15.1-20.0 38 20.1+ 13 Elevated creatinine (maximum/mg %) 2.1-6.0 637 6.1-10.0 85 10.1— 10 Hematuria (gross) 2 Edema (symptomatic nerve or vessel compression) 17 Tissue ischemia 2 Resp. distress: not intubated 67 intubated 41 Bronchospasm 9 Pleural effusion (requiring thoracentesis) 17 Somnolence 114 Coma 33 Disorientation 215 Hypotension (requiring pressors) 508 Angina 22 Myocardial infarction 6 Arrhythmias 78 Anemia requiring transfusion (number units transfused) 1-15 377 6-10 95 11-15 24 16+ 14 Thrombocytopenia (minimum/mm3) <20,000 131 20,001-60,000 361 60,001-100,00 285 Central line sepsis 63 Death 10 - IL-2 (Chiron), NSC #373364, is provided as a 5 mL vial containing 1.3 mg of protein as a lyophilized powder cake, with
mannitol 50 mg and Sodium Dodecyl Sulfate 130 μg per milligram of protein. The 1.3 mg of protein is equivalent to approximately 21.6 million International Units (IU) or 3.6 million Cetus units (CU), where 600 IU=100 CU. The vial is reconstituted with 2.0 mL of Sterile Water for Injection, USP, and the resultant concentration is 10.8 million IU/ml or 1.8 million CU/ml. Diluent should be directed against the side of the vial to avoid excess foaming. Contents are gently swirled, not shaken, until completely dissolved. Since vials contain no preservative, reconstituted solution should be used with 8 hours. - Intact vials are stored in the refrigerator (2-8° C.) protected from light. Each vial bears an expiration date.
- Reconstituted IL-2 is further diluted with 50 mL of 5% Human Serum Albumin (HSA). The HSA is added to the diluent prior to the addition of recombinant IL-2. Dilutions of the reconstituted solution over a 1000-fold range (i.e., 1 mg/mL to 1 μg/mL) are acceptable in either glass bottles or polyvinyl chloride bags. Reconstituted solutions are not mixed with saline-containing solutions. IL-2 is chemically stable for 48 hours at refrigerated and room temperatures, 2-30° C.
- All patients receiving IL-2 also receive concomitant medications to relieve side effects as in all previous high-dose IL-2 protocols. The following concomitant medication begins the evening before the first dose of IL-2 and continues throughout the entire cycle of treatment: acetaminophen (650 mg every 4 hr), indomethacin (50-75 mg every 6-8 hr), and ranitidine (150 mg every 12 hr). Patients receive intravenous meperidine (25 to 50 mg) to control chills when they occur, although chills are unusual after the first one to two doses of IL-2. Ondansetron, droperidol, or scopolamine is available as needed for the treatment of nausea during treatment. Steroids are not used in these patients and if steroids are required then the patient should be taken off protocol therapy.
- If PBL fail to expand to adequate numbers, then cultures may be expanded using 1000 CU/ml IL-2 or the “Rapid Expansion Protocol” (REP) as described below: MOv-transduced PBL are counted and the specified number is used (Table 13). In the REP cycle immediately preceding infusion, 1.25 mg/ml Fungizone and 1 ml/L Cipro are added on
day 8, and AIM V media is used. - On
day 0 PBMC are thawed, washed twice in AIM V media, resuspended in complete media (CM; RPMI media) and irradiated (340 Gy) as described above. PBMC and OKT3 are added to CM, mixed well, and aliquots are transferred to tissue culture flasks. Viable cells are added last. Flasks are incubated upright at 37° C. in 5% CO2. - On
day 2 IL-2 is added to a final concentration of 50 CU/ml. - On
day 5 20 ml (130 ml for a 175 cm2 flask) of culture supernatant is removed by aspiration (cells are retained on the bottom of the flask). Media is replaced with CM containing 50 CU/ml IL-2. - On
day 8, an aliquot of cells is removed for counting and is further analyzed (ELISA, FACS, etc.). If cell density is greater than 1×106/ml, cells are split into additional flasks or transferred toBaxter 3 liter culture bags. IL-2 is added to 50 CU/ml. Fungizone is added to a final concentration of 1.25 mg/ml and 1 ml/L Cipro is added. - On
day 11, IL-2 is added to a final concentration of 50 CU/ml. Cells are split if density exceeds 1.5×106 cells/ml. - On day 14, cells are harvested and either prepared for additional REP cycles or cryopreserved. In general, REP expansion of CTL clones results in 50-200 fold expansion. Thus, 2-3 REP cycles could be required to generate a sufficient number of cells for patient treatment. If cells have grown to sufficient numbers for patient treatment, a sample is collected from each flask for microbiology tests 2-3 days before the beginning of PBL therapy (the test takes 2 days). IL-2 is added to a final concentration of 50 CU/ml on day 14 and every 3 days until the final product is prepared for infusion.
-
TABLE 13 Component 25 cm2 flask 150 cm2 flask viable transduced PBL 1 × 105 1 × 106 allogeneic PBMC 2.5 × 107 2 × 108 OKT3 30 ng/ml 30 ng/ ml CM 25 ml 75 ml AIM V 75 ml - A complete response is defined as the disappearance of all clinical evidence of disease that lasts at least four weeks. Partial response is defined as a 50% or greater decrease in the sum of the products of the maximal perpendicular diameter of all measurable lesions for at least four weeks with no appearance of new lesions or increase in any lesions. A minor response is defined as a 25-49% decrease in the sum of the products of the maximal perpendicular diameters of all measurable lesions but no appearance of new lesions and no increase in any lesion.
- Any patient with less than a minor response will be considered a nonresponder. The appearance of a new lesion or a greater than 25% increase in the product of perpendicular diameters of any prior lesion following a partial or complete response will be considered a relapse.
- Retroviral supernatant containing the MOv-γ chimeric receptor gene was used for lymphocyte transductions (Retroviral supernatant to be produced by Somatix, Inc, Alameda Calif.).
- For the generation of high-titer recombinant viral vector encoding the MOv-γ chimeric receptor, the MFG-S retroviral vector and the ψ-CRIP packaging cell line were used (Danos, O. and R. C. Mulligan. Proc. Natl. Acad. Sci. U.S.A., 85:6460-6464, 1988), similar to that approved for use in ongoing clinical trials (Jaffee, et al. Cancer Res., 53:2221-2226, 1993). In the MFG-S vector, Moloney murine leukemia virus (MoMLV) long terminal repeat (LTR) sequences were used to generate both a full length viral RNA necessary for the generation of viral particles and a subgenomic mRNA analogous to the MO-MuLV envelope RNA, which is responsible for the expression of the MOv-γ gene (
FIG. 15 ). The vector retained sequences in both the viral gag region shown to improve the encapsidation of viral RNA and the normal viral 5′ and 3′ splice sites necessary for generation of the subgenomic RNA. Three additional point mutations were introduced into the viral gag region to eliminate the potential expression of two overlapping open reading frames (ORFs), which encode the NH2 portion of both the cell surface and cytoplasmic gag-pol polyproteins. DNA sequences encoding MOv-γ were inserted such that the initiation codon of the inserted sequences was placed precisely at the position normally occupied by the initiation codon for env translation, and minimal 3′ non-translated sequences were included in the insert. The entire DNA sequence from LTR to LTR was determined for both strands of the vector and no mutations or base substitutions were discovered. - The T-CRIP cell line provided the viral proteins necessary for encapsidation of recombinant retroviral genomes into infectious particles. As is the case with other packaging cell lines, the expression of the relevant viral gene products in Ψ-CRIP cells is accomplished in a manner designed to prevent the encapsidation and mobilization of the RNA molecules encoding the viral gene products. This makes possible the generation of stocks of replication-deficient recombinant virus, free of replication-competent virus.
- High titer stocks of recombinant virus suitable for clinical use were generated from cultures derived from the working cell bank (WBC) propagated in a closed-loop perfusion system designed for the mass culture of anchorage dependent cells. The system allowed the culture medium to be monitored for perfusion rate, oxygen levels, and pH, permitting the growth and maintenance of large numbers of cells in a minimal volume of medium. In its current configuration, approximately 5×1010 cells were cultured in a single vessel which minimized the risk of contamination from handling multiple flasks, and additionally ensured a consistent lot of recombinant virus.
- To initiate a production run, a vial of the WCB of the producing cell line was thawed and expanded in culture to generate sufficient numbers of cells to seed the bioreactor. During this brief scale-up period, the cells were re-tested for sterility and mycoplasma contamination. The system was then seeded and monitored until the optimal cell density is achieved. At this point, fresh culture supernatant was collected, filtered, and stored in frozen aliquots for quality control and safety testing as required for FDA approval, followed by clinical use.
- The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of one of ordinary skill in the art.
Claims (31)
1. A composition comprising a T lymphocyte having a chimeric receptor or T-cell receptor reactive with a tumor antigen and an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte.
2-3. (canceled)
4. The composition of claim 1 wherein the tumor antigen is an ovarian tumor antigen.
5. The composition of claim 1 wherein the tumor antigen is a melanoma antigen.
6. (canceled)
7. The composition of claim 1 wherein the chimeric receptor is a single chain Fv receptor.
8. The composition of claim 1 wherein the allogeneic cell is an allogeneic peripheral blood cell.
9. (canceled)
10. The composition of claim 1 wherein the chimeric receptor is Mov-γ.
11. (canceled)
12. A lymphocyte comprising a T-cell receptor reactive with an allogeneic cell and a chimeric receptor reactive with a tumor antigen, wherein the lymphocyte is activated in vivo with the allogeneic cell.
13.-14. (canceled)
15. The lymphocyte according to claim 12 wherein the allogeneic cell is a peripheral blood cell.
16.-39. (canceled)
40. A pharmaceutical composition comprising:
a T lymphocyte comprising a chimeric receptor reactive with a tumor antigen and an endogenous T-cell receptor reactive with a cell that is allogeneic to the T lymphocyte; and
a pharmaceutically acceptable carrier.
41.-43. (canceled)
44. The composition of claim 4 , wherein the ovarian tumor antigen is folate binding protein (FBP).
45. The composition of claim 1 , wherein the T lymphocyte is a human T lymphocyte.
46. The lymphocyte of claim 12 , wherein the lymphocyte is a human lymphocyte.
47. The lymphocyte of claim 12 , wherein the tumor antigen is an ovarian tumor antigen.
48. The lymphocyte of claim 47 , wherein the ovarian tumor antigen is FBP.
49. The lymphocyte of claim 12 , wherein the chimeric receptor is Mov-γ.
50. A pharmaceutical composition comprising the lymphocyte of claim 12 and a pharmaceutically acceptable carrier.
51. A composition comprising the lymphocytes prepared by
selecting for lymphocytes reactive with an allogeneic cell ex vivo; and
transducing the lymphocytes with a chimeric receptor gene, said gene encoding a receptor which is reactive with a tumor antigen.
52. A composition comprising a population of T lymphocytes comprising
(a) a chimeric receptor or T cell receptor that is reactive with a tumor antigen, and
(b) a T-cell receptor that is reactive with an allogeneic cell,
wherein the population of T lymphocytes has been exposed to a cell that is allogeneic to an individual or subpopulation of T lymphocytes of the population under conditions which expand and activate the individual or subpopulation of T lymphocytes.
53. The composition of claim 52 , wherein the tumor antigen is an ovarian tumor antigen.
54. The composition of claim 53 , wherein the ovarian tumor antigen is folate binding protein (FBP).
55. The composition of claim 52 , wherein the cell is a peripheral blood mononuclear cell, splenocyte, a dendritic cell, or a B cell.
56. The composition of claim 52 , wherein the T lymphocyte is a human T lymphocyte.
57. The composition of claim 52 , wherein the population further comprises the cell that is allogeneic to the T lymphocytes.
58. The composition of claim 51 , further comprising the cell that is allogeneic to the lymphocytes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/715,829 US20100158881A1 (en) | 2001-03-09 | 2010-03-02 | Activated dual specificity lymphocytes and their methods of use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/803,578 US7723111B2 (en) | 2001-03-09 | 2001-03-09 | Activated dual specificity lymphocytes and their methods of use |
US12/715,829 US20100158881A1 (en) | 2001-03-09 | 2010-03-02 | Activated dual specificity lymphocytes and their methods of use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/803,578 Continuation US7723111B2 (en) | 2001-03-09 | 2001-03-09 | Activated dual specificity lymphocytes and their methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100158881A1 true US20100158881A1 (en) | 2010-06-24 |
Family
ID=25186900
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/803,578 Expired - Fee Related US7723111B2 (en) | 2001-03-09 | 2001-03-09 | Activated dual specificity lymphocytes and their methods of use |
US12/715,829 Abandoned US20100158881A1 (en) | 2001-03-09 | 2010-03-02 | Activated dual specificity lymphocytes and their methods of use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/803,578 Expired - Fee Related US7723111B2 (en) | 2001-03-09 | 2001-03-09 | Activated dual specificity lymphocytes and their methods of use |
Country Status (5)
Country | Link |
---|---|
US (2) | US7723111B2 (en) |
EP (1) | EP1379670B1 (en) |
AT (1) | ATE403734T1 (en) |
DE (1) | DE60228068D1 (en) |
WO (1) | WO2002072850A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014725A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
WO2019060425A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
WO2021183675A2 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7723111B2 (en) * | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
WO2006004592A2 (en) * | 2004-05-28 | 2006-01-12 | Mayo Foundation For Medical Education And Research | Methods for autologous stem cell transplantation |
PT1809321E (en) * | 2004-10-08 | 2012-05-17 | Us Gov Health & Human Serv | Adoptive immunotherapy with enhanced t lymphocyte survival |
EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
US8318153B2 (en) * | 2006-06-29 | 2012-11-27 | Nalin David R | Method of medically treating an individual |
US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
US7914263B2 (en) | 2007-05-14 | 2011-03-29 | Vladimir Berger | Ejector-type rotary device |
US8501003B2 (en) * | 2007-10-17 | 2013-08-06 | Caterpillar Inc. | Canister filter system with drain that cooperates with filter element |
WO2009126789A2 (en) | 2008-04-09 | 2009-10-15 | Maxcyte, Inc. | Engineering and delivery of therapeutic compositions of freshly isolated cells |
CA2824997C (en) | 2011-01-18 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
WO2017004252A1 (en) | 2015-06-30 | 2017-01-05 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Redirected cells with mhc chimeric receptors and methods of use in immunotherapy |
US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
JP2019500028A (en) | 2015-11-19 | 2019-01-10 | ブラッドセンター リサーチ ファウンデーション | Method for producing bispecific T cells for use in cancer immunotherapy |
CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
US11850262B2 (en) | 2017-02-28 | 2023-12-26 | Purdue Research Foundation | Compositions and methods for CAR T cell therapy |
AU2018256436A1 (en) | 2017-04-19 | 2019-11-07 | Board Of Regents, The University Of Texas System | Immune cells expressing engineered antigen receptors |
WO2019006418A2 (en) | 2017-06-30 | 2019-01-03 | Intima Bioscience, Inc. | Adeno-associated viral vectors for gene therapy |
WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
JP7417542B2 (en) | 2018-01-22 | 2024-01-18 | シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) | How to use CAR T cells |
CN111549044B (en) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | Preparation method and application of targeted TRBC1 CAR-T cell |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5359046A (en) * | 1990-12-14 | 1994-10-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
US5844075A (en) * | 1994-04-22 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US6407221B1 (en) * | 1990-12-14 | 2002-06-18 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US6410319B1 (en) * | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US20020137697A1 (en) * | 1992-03-18 | 2002-09-26 | Zelig A. Eshhar | Chimeric receptor genes and cells transformed therewith |
US20030026790A1 (en) * | 2001-03-09 | 2003-02-06 | Patrick Hwu | Activated dual specificity lymphocytes and their methods of use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3687014T2 (en) | 1985-05-01 | 1993-04-01 | Asahi Chemical Ind | TO DETECT TUMORS CAPABLE OF A CLONED T-CELL AND A T-CELL ANTIGEN RECEPTOR. |
IL86278A (en) | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
IE920716A1 (en) | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
WO1993019163A1 (en) | 1992-03-18 | 1993-09-30 | Yeda Research And Development Co, Ltd. | Chimeric receptor genes and cells transformed therewith |
EP0716570A4 (en) | 1993-09-03 | 1997-12-17 | Systemix Inc | Genetically modified human hematopoietic stem cells and their progeny |
-
2001
- 2001-03-09 US US09/803,578 patent/US7723111B2/en not_active Expired - Fee Related
-
2002
- 2002-03-08 AT AT02721335T patent/ATE403734T1/en not_active IP Right Cessation
- 2002-03-08 EP EP02721335A patent/EP1379670B1/en not_active Expired - Lifetime
- 2002-03-08 WO PCT/US2002/007249 patent/WO2002072850A1/en not_active Application Discontinuation
- 2002-03-08 DE DE60228068T patent/DE60228068D1/en not_active Expired - Lifetime
-
2010
- 2010-03-02 US US12/715,829 patent/US20100158881A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5359046A (en) * | 1990-12-14 | 1994-10-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US6407221B1 (en) * | 1990-12-14 | 2002-06-18 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US20020137697A1 (en) * | 1992-03-18 | 2002-09-26 | Zelig A. Eshhar | Chimeric receptor genes and cells transformed therewith |
US5844075A (en) * | 1994-04-22 | 1998-12-01 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
US5830755A (en) * | 1995-03-27 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | T-cell receptors and their use in therapeutic and diagnostic methods |
WO1998016238A2 (en) * | 1996-10-11 | 1998-04-23 | The Regents Of The University Of California | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
US6410319B1 (en) * | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US20030026790A1 (en) * | 2001-03-09 | 2003-02-06 | Patrick Hwu | Activated dual specificity lymphocytes and their methods of use |
US7723111B2 (en) * | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
Non-Patent Citations (2)
Title |
---|
Bartels et al., Adoptive Cellular Immunotherapy of Cancer in Mice Using Allogeneic T-Cells. Annals of Surgical Oncology, 1996, 3(1):67-73 * |
Topalian, S., L. Muul, D. Solomon, and S.A. Rosenberg. 1987. Expansion of human tumor infiltrating lymphocytes for usein immunotherapy trials. J. Immunol. Methods. 102:127. * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016014725A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
US10526391B2 (en) | 2014-07-22 | 2020-01-07 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
WO2019060425A1 (en) | 2017-09-19 | 2019-03-28 | Massachusetts Institute Of Technology | Compositions for chimeric antigen receptor t cell therapy and uses thereof |
WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
WO2021183675A2 (en) | 2020-03-10 | 2021-09-16 | Massachusetts Institute Of Technology | Methods for generating engineered memory-like nk cells and compositions thereof |
WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
WO2021221782A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Chimeric antigen receptor-targeting ligands and uses thereof |
WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
Also Published As
Publication number | Publication date |
---|---|
DE60228068D1 (en) | 2008-09-18 |
EP1379670A1 (en) | 2004-01-14 |
WO2002072850A1 (en) | 2002-09-19 |
US7723111B2 (en) | 2010-05-25 |
ATE403734T1 (en) | 2008-08-15 |
US20030026790A1 (en) | 2003-02-06 |
EP1379670B1 (en) | 2008-08-06 |
EP1379670A4 (en) | 2004-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7723111B2 (en) | Activated dual specificity lymphocytes and their methods of use | |
US7915036B2 (en) | Compositions comprising T cell receptors and methods of use thereof | |
JP6230208B2 (en) | Stimulation of anti-tumor immunity using dendritic cell / tumor cell fusions and anti-CD3 / CD28 | |
US7670611B2 (en) | Cancer immunotherapy with semi-allogeneic cells | |
JP2011504101A5 (en) | ||
KR20080077272A (en) | Methods for generating antigen-specific effector t cells | |
CA2192655A1 (en) | Methods for in vivo t cell activation by antigen-pulsed dendritic cells | |
CN109776671B (en) | Isolated T cell receptor, modified cell thereof, encoding nucleic acid, expression vector, preparation method, pharmaceutical composition and application | |
CN110857319B (en) | Isolated T cell receptor, modified cell, encoding nucleic acid and application thereof | |
US20220202862A1 (en) | Cd8 polypeptides, compositions, and methods of using thereof | |
AU2016243626A1 (en) | Compositions and methods of treating multiple myeloma | |
US8444965B2 (en) | Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines | |
US20040260061A1 (en) | Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity | |
AU2016243194A1 (en) | Compositions and methods of treating acute myeloid leukemia | |
US7381405B2 (en) | Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer | |
KR20080106193A (en) | Dendritic cells transiently transfected with a membrane homing polypeptide and their use | |
US20240066127A1 (en) | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof | |
US20230348561A1 (en) | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof | |
US20230348548A1 (en) | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof | |
CA2501087C (en) | Methods of preparing lymphocytes that express interleukin-2 and their use in the treatment of cancer | |
AU2021411495A1 (en) | Cd8 polypeptides, compositions, and methods of using thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |